All publications and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Described herein are implantable microstimulators (e.g., neural stimulation systems and devices) that may include a static magnetic field detector for emergency shut-off of the implant. These implants may be configured to negotiate with an external charger (via inductive coils) to control charging power based at least in part an estimate of implant temperature, e.g., surface temperature, derived by the charger. The implant may alternatively or additionally negotiate the charging level provided by the charger to extend communication between the implant and the charger. In particular, the apparatuses (systems and devices, including implants and/or chargers) described herein may be configured for electrically stimulating one or more nerves (e.g., the vagus nerve) to treat chronic inflammation by modulation of the inflammatory response (via the nicotinic cholinergic anti-inflammatory pathway)
Implantable electrical stimulation devices have been developed for therapeutic treatment of a wide variety of diseases and disorders. For example, implantable cardioverter defibrillators (ICDs) have been used in the treatment of various cardiac conditions. Spinal cord stimulators (SCS), or dorsal column stimulators (DCS), have been used in the treatment of chronic pain disorders including failed back syndrome, complex regional pain syndrome, and peripheral neuropathy. Peripheral nerve stimulation (PNS) systems have been used in the treatment of chronic pain syndromes and other diseases and disorders. Functional electrical stimulation (FES) systems have been used to restore some functionality to otherwise paralyzed extremities in spinal cord injury patients.
Typical implantable electrical stimulation systems may include one or more programmable electrodes on a lead that are connected to an implantable pulse generator (IPG) that contains a power source and stimulation circuitry. However, these systems can be difficult and/or time consuming to implant, as the electrodes and the IPG are usually implanted in separate areas and therefore the lead must be tunneled through body tissue to connect the IPG to the electrodes. Also, leads are susceptible to mechanical damage over time, particularly as they are usually thin and long.
Recently, small implantable neural stimulator technology, i.e. microstimulators, having integral electrodes attached to the body of a stimulator has been developed to address the disadvantages described above. This technology allows the typical IPG, lead and electrodes described above to be replaced with a single integral device. Integration of the lead has several advantages including reduction of surgery time by eliminating, for example, the need for implanting the electrodes and IPG in separate places, the need for a device pocket, the need for tunneling to the electrode site, and requirements for strain relief ties on the lead itself. Reliability may therefore be increased significantly, especially in soft tissue and across joints because active components, such as lead wires, are now part of the rigid structure and are not subject to the mechanical damage due to repeated bending or flexing over time.
Unfortunately, the currently developed leadless devices tend to be larger and more massive than desirable, and even than traditional electrode/lead assemblies, making it difficult to stably position such devices in the proper position with respect to the nerve. Without device stability, the nerve and/or surrounding muscle or tissue can be damaged due to movement of the assembly. Further these devices require long charging times, and are often difficult to control (e.g., program) and regulate. There remains a need for leadless integral microstimulator devices that can be stably positioned on the nerve and regulate their power, including power delivered by an outside charger to inductively charge the implant.
The power requirement of implantable neurostimulators may be highly limiting. The greater the power required, the longer the charging time, and the larger the implant (e.g., battery, capacitor, etc.) must be. In addition, because these devices are implanted, they must be protected or constrained from heating above internal body temperature more than a minimum amount (e.g., 2° C.), or risk damaging tissues. This may be particularly challenging when inductive charging is used to charge the implant.
Moreover, there might be unexpected situations such as circuit dysfunction or failure, sudden health condition change of the patient, unusual environment, thermistor failure, etc. A manual shut-off of the microstimulator may be needed in such emergency situations. There is a need for a manual shut off of the implantable microstimulator to protect the patients in case of emergency.
Described herein are microstimulators (MS, also referred to herein as neurostimulators, microregulators, MRs, etc.) and methods of using them that may address some of the needs identified above.
Described herein are systems for the treatment of chronic inflammatory disorders that include an implantable microstimulator with a static magnetic field detector.
Any of these apparatuses may include a detector for detecting a static magnetic field of a predetermined strength to disable (e.g., turn “off”, suspend, disable or prevent stimulation from the device). For example, disclosed herein include a leadless, implantable microstimulator devices (neurostimulators) for treating chronic inflammation that are configured to have an emergency shut-off that may be triggered by a predetermined static magnetic field that is externally applied near the implant. In particular, described herein are implants that are based on non-hall effect sensors for detecting the static magnetic field. This is because Hall effect sensors are typically larger and may not be appropriate for the very small, compact and low-energy neurostimulator implants described herein.
In general, the device can comprise a hermetically sealed capsule body, at least two electrically conductive capsule regions, wherein each region electrically connects to an electrode for applying stimulation to a vagus nerve. The implantable microstimulator device can comprise a resonator within the sealed capsule body. The resonator can comprise a coil and a capacitor configured to resonate at a predetermined frequency range.
The implantable microstimulator device can comprise a static magnetic field detector. The static magnetic field detector can comprise a low power pulse generator to generate pulses at the predetermined frequency range, the pulses configured to be introduced into the resonator, and a detection circuit configured to monitor a decay rate of the pulses. The implantable microstimulator device can further comprise a battery within the sealed capsule body, and an electronic assembly within the sealed capsule body. The electronic assembly comprises power management circuitry configured to receive power from the resonator to charge the battery, a microcontroller configured to control stimulation of the vagus nerve from the conductive capsule regions, and an emergency shut-off control configured to shut down the device when the decay rate increases to a predetermined threshold decay rate.
In some variations, a magnet can be placed near the implantable microstimulator to trigger the static magnetic field detector and cause an emergency shut off of the microstimulator. In some variations, the static magnetic field detector can comprise a resonator built in the microstimulator. The resonator can utilize an antenna, which is configured to receive power from an external charger. The antenna can comprise a coil of wire with a ferrite core to form an inductor with a defined inductance. This inductor can be coupled with a capacitor and a resistance to form a resonant circuit (RLC circuit). An external high quality NPO capacitor can be used to set the tank frequency. The frequency can be set to that of the radiated electric field to receive power and data from the external source. For example, the resonator can be a coil and capacitor configured to resonate at about 131 KHz+/−2%. The coil can be constructed with many turns of magnet wire with a target inductance of about 20 uH.
The static magnetic field detector can comprise a low power pulse generator. For example, the pulse generator can be an ultra-low power pulse generator based on a ring oscillator with the power between 1 nanowatt and 10 microwatts. In some other variations, the power of the pulse generator can be between 1 nanowatt and 1 microwatt. The low power pulse from the pulse generator can be introduced into the coil or the resonator RLC circuit. When the coil is tuned, the low power pulses can take a relatively long time to decay. But when a magnetic field is introduced to the coil, the coil is detuned. Therefore, the decay rate is much quicker (or time constant is smaller).
The static magnetic field detector can further comprise a detection circuit. The detection circuit can be configured to monitor the decay rate of the pulses or time constant of the resonator. The static magnetic field detector can be configured to shut down the microstimulator when the decay rate is increased to a predetermined value. The static magnetic field detector can be configured to shut down the microstimulator when the decay rate is 1.5, 2, 2.5, 3, 4, 5, 10 times of the previous value or any values therebetween. Values outside the above range are also possible. In some variation, the static magnetic field detector can be configured to shut down the microstimulator by using h a shorting switch. In some variations, the low power pulses can be introduced periodically, such as every second, to detect the presence of the magnetic field. In some other variations, the low pulses can be introduced continuously to monitoring the presence of the magnetic field.
In some variations the static magnetic field is detected using a Wiegand material (e.g., a material, such as a Wiegand wire exhibiting the Wiegand effect).
Methods of shutting down an implantable microstimulator device are also described herein. For example, described herein are methods of shut down an implantable microstimulator device by using a static magnetic field detector.
In some variations these methods may include the steps of: generating pulses by a low power pulse generator, introducing the pulses into an RLC resonator, monitoring a decay rate of the pulses, and shutting down the device when the decay rate increases to a predetermined threshold decay rate.
In some variations, the method of shutting down the device by the static magnetic field detector can comprise utilizing a built-in receiving coil of the microstimulator. In some other variations, the method can comprise utilizing another RLC resonator of the microstimulator.
In some variation, the method can comprise placing a magnet near the device. In some variation, the method can further comprise shutting down the device when the predetermined threshold decay rate increases 1.5, 2, 5, 10 times any values therebetween. In some variation, the method can comprise using a shorting switch configured to shut down the device.
In some variation, a power of the pulses from the low pulse generator is between 1 nanowatt and 10 microwatts. In some other variation, a power of the pulses is between 1 nanowatt and 1 microwatts. In some variation, the low power pulses are introduced periodically. In some other variation, the low power pulses are introduced continuously.
The above summary of the invention is not intended to describe each illustrated embodiment or every implementation of the present invention, but to highlight certain key features. The figures and the detailed description that follow more particularly exemplify these embodiments and features.
In addition or alternatively, any of the neurostimulators and chargers for charging these neurostimulators described herein include control circuitry that negotiates and controls the power applied by the charger to prevent overheating of the implanted neurostimulator, while still rapidly and efficiently charging the implant. For example, described herein are chargers for inductively charging a neurostimulator implanted within a portion of the patient's body. A charger may include: an energizer coil; an amplifier configured to drive an electrical current through the energizer coil to generate an electromagnetic field; and a controller comprising a power control loop configured to modulate the electrical current driven through the energizer coil based on an estimate of a tank voltage of the neurostimulator (PWRIN), to prevent a surface temperature of the neurostimulator from exceeding a predetermined threshold relative to the body temperature of the patient.
A charger for inductively charging a neurostimulator implanted within a portion of the patient's body may also or alternatively include: an energizer coil; an amplifier configured to drive an electrical current through the energizer coil to generate an electromagnetic field; and a controller comprising a power control loop configured to modulate the electrical current driven through the energizer coil such that a surface temperature of the neurostimulator remains within about 2 degrees Celsius of the body temperature of the patient.
The power control loop may be configured to modulate the electrical current driven through the energizer coil based on a measurement of a change in voltage across the energizer coil when the energizer coil is in an unloaded state and a loaded state from charging the neurostimulator.
The power control loop may be configured to modulate the electrical current driven through the energizer coil based on a power control loop parameter, wherein the power control loop parameter is based on a set power level of the amplifier and a measurement of a change in voltage across the energizer coil when the energizer coil is in an unloaded state and a loaded state from charging the neurostimulator.
In some variations, the set power level and change in voltage may be multiplied together to yield the power control loop parameter.
The power control loop may be configured to modulate the current driven through the energizer coil such that the power control loop parameter is maintained at approximately a predetermined target value. The predetermined target value may be based on an identification of the charger and the neurostimulator. The predetermined target value may further be based on an identification of one or more characteristics of the inductive coupling between the charger and the neurostimulator. The power control loop may be configured to duty cycle the electric current driven through the energizer coil when the change in voltage across the energizer coil is not detected. The power control loop may further comprise a pulse width modulator, wherein the pulse width modulator is configured to be duty cycled when the change in voltage across the energizer coil is not detected. The power control loop may be configured to duty cycle the electric current driven through the energizer coil when the T×H is greater than a predetermined value.
Also described herein are methods of inductively charging a microstimulator with a charger. For example a method of charging (e.g., to prevent overheating of the outside of the implant above a few degrees) may include: determining a change in voltage across an energizer coil of the charger when the energizer coil is in an unloaded state and a loaded state; and modulating a set power level of the energizer coil based on the determined changed in voltage across the energizer coil.
The power level may be modulated by setting the power level such that the power level multiplied by the change in voltage equals a predetermined value.
Any of these methods may include duty cycling the energizer coil when the change in voltage is not detected, and/or determining the charger type and the microstimulator type. The power level may be modulated by setting the power level such that the power level multiplied by the change in voltage equals a predetermined value, wherein the predetermined value is based on the charger type and the microstimulator type.
Although the implants described herein are shown and described as implantable in the neck (e.g., carotid) region of the vagus nerve, any of these implants may be inserted in other body regions, including in particular the subdiaphragmatic region (see, e.g., U.S. patent application Ser. No. 15/433,936). Furthermore, the implants described typically include batteries; in some variations any of these implants may not include a battery (e.g., “batteryless” implants that may apply stimulation in the presence of the inductive field, also described in U.S. patent application Ser. No. 15/433,936, herein incorporated by reference in its entirety).
Systems for electrically stimulating one or more nerves to treat chronic inflammation may include an implantable, wireless microstimulator such as those described herein and an external charging device (which may be referred to as a charging wand, charger, or energizer). In some variations the system also includes a controller such as a “prescription pad” that helps control and regulate the dose delivered by the system. The microstimulator may be secured in position using a securing device (which may be referred to as a “POD”) to hold the microstimulator in position around or adjacent to a nerve. These microstimulators are designed and adapted for treatment of chronic inflammation, and may be configured specifically for such use. Thus, an implantable microstimulator may be small, and adapted for the low duty-cycle stimulation to modulate inflammation. For example, the implantable microstimulator may hold a relatively small amount of power over weeks or even months and discharge it at a rate sufficient to modulate the anti-inflammatory pathway without significantly depressing heart rate or triggering any number of unwanted effects from the vagus nerve or other neural connections. Any of the nerves of the inflammatory reflex, including the vagus nerve, may be treated as described herein using the systems described.
Any of these apparatuses (systems and devices, including microstimulators and chargers) may be adapted to include one or more of an emergency shutoff, which may be based on a static magnetic field detector, and/or a thermal control or regulation based on the power in (“PWRIN”) of the microstimulator. The thermal regulator may be configured to modulate the power applied by the inductive coupling between the external charger and the microstimulator (implant), as will be described in greater detail below. In general, the microstimulator may include a power negotiation protocol. This protocol may be hardware, firmware and/or software, and may regulate charger function, including switching the charger on or off (including altering the duty cycle of the charger). The power negotiation protocol may be on the charger, the microstimulator, or both. For example, a controller of the microstimulator may execute a power negotiation protocol to negotiate at whap power the battery will charge at. The microstimulator may exchange data with and between the charger, at least in part to negotiate what power level the MS will draw power from the charger; if the MS attempts to draw too much power from the charger, it may delay or stop communication between the MS and the charger. Thus, the power negotiation protocol may throttle down the power drawn by the MS, thereby extending communication between the MR and the charger, permitting further telemetry. Initially, the charger and implant may exchange identifying information, such as charger type (capability, e.g., coil size, etc.), implant type (e.g., inductive coil size(s), etc.), coupling between the two, etc. Once communication has been initiated, the apparatus may then negotiate what level the charger will charge the implant (e.g., what applied voltage, current, power, etc.).
Any of these apparatuses may use an intermediate field communication link (e.g., when the implant is running off of a battery), including a high-gain amplifier to amplify an RF signal from the charger, using the battery rather than charging it during initial communication between the charger and implant, which may allow longer range.
As mentioned, in general, the apparatuses described herein may include an implant (microstimulator) and a charger. For example,
In general, the systems described herein may be configured to apply electrical stimulation at a minimum level necessary to modulate the inflammatory reflex (e.g., modulating cytokine release) characterized by the Chronaxie and rheobase. Chronaxie typically refers to the minimum time over which an electric current double the strength of the rheobase needs to be applied in order to stimulate the neuron. Rheobase is the minimal electrical current of infinite duration that results in an action potential. As used herein, cytokines refer to a category of signaling proteins and glycoproteins that, like hormones and neurotransmitters, are used extensively in cellular communication.
The NCAP Systems described herein are typically intended for the treatment of chronic inflammation through the use of implanted neural stimulation devices (microstimulators) to affect the Neural Stimulation of the Cholinergic Anti-inflammatory Pathway (NCAP) as a potential therapeutic intervention for rheumatologic and other inflammation-mediated diseases and disorders. Neurostimulation of the Cholinergic Anti-inflammatory Pathway (NCAP) has been shown to modulate inflammation. Thus, the treatment and management of symptoms manifested from the onset of disease (e.g., inflammatory disease) is based upon the concept of modulating the Cholinergic Anti-inflammatory Pathway. The NCAP pathway normally maintains precise restraint of the circulating immune cells. As used herein, the CAP is a reflex that utilizes cholinergic nerve signals traveling via the Vagus nerve between the brain, chemoreceptors, and the reticuloendothelial system (e.g., spleen, liver). Local release of pro-inflammatory cytokines (e.g., tumor necrosis factor or TNF) from resident immune cells is inhibited by the efferent, or indirectly by afferent vagus nerve signals. NCAP causes important changes in the function and microenvironment of the spleen, liver and other reticuloendothelial organs. Leukocytes which circulate systemically become “educated” as they traverse the liver and spleen are thereby functionally down regulated by the affected environment of the reticuloendothelial system. This effect can potentially occur even in the absence of an inflammatory condition.
Under this model, remote inflammation is then dampened by down-regulated cytokine levels. Stimulation of the vagus nerve with a specific regiment of electrical pulses regulates production of pro-inflammatory cytokines. In-turn, the down regulation of these cytokines may reduce localized inflammation in joints and other organs of patients with autoimmune and inflammatory disorders.
The NCAP System includes a neurostimulator that may trigger the CAP by stimulating the cervical vagus nerve. The NCAP System issues a timed burst of current controlled pulses with sufficient amplitude to trigger the CAP at a particular interval. These two parameters, Dose Amplitude and Dose Interval, may be used by a clinician to adjust the device. For example, the clinician may set the Dose Amplitude by modifying the current level. The Dose Interval may be set by changing the duration between Doses (e.g. 12, 24, 48 hours).
In some variations, dose amplitude may be set to within the Therapy Window. The Therapy window is defined as the lower limit of current necessary to trigger the CAP, and the upper limit is the level at which the Patient feels uncomfortable. The lower limit is called the Threshold (T), and the uncomfortable level is called Upper Comfort Level (UCL).
Dose Amplitude thresholds are nonlinearly dependent upon Current (I), Pulse width (PW), Pulse Frequency (PF), and Burst Duration (BD). Amplitude is primarily set by charge (Q), that is Current (I)×Pulse width (PW). In neurostimulation applications current has the most linear relationship when determining thresholds and working within the therapy window. Therefore, the clinician may modify Dose Amplitude by modifying current. The other parameters are held to experimentally determined defaults. Pulse width is selected to be narrow enough to minimize muscle recruitment and wide enough to be well above the chronaxie of the targeted neurons. Stimulus duration and pulse frequency was determined experimentally in Preclinical work.
Dose Interval may be specific for particular diseases and the intensity of diseases experienced by a patient. Our initial research has indicated that the cervical portion of the vagus nerve may be an ideal anatomic location for delivery of stimulation. The nerve runs through the carotid sheath parallel to the internal jugular vein and carotid artery. At this location, excitation thresholds for the vagus are low, and the nerve is surgically accessible. We have not found any significant difference in biomarker modulation (e.g., modulation of cytokines) between right and left. Even though the right vagus is thought to have lower thresholds than the left in triggering cardiac dysrythmias, the thresholds necessary for NCAP are much lower than those expected to cause such dysrythmias. Therefore a device delivering NCAP can safely be applied to either the right or left vagus.
We have also found, surprisingly, that the Therapy Window is maximized on the cervical vagus through the use of a bipolar cuff electrode design. Key parameters of the cuff may be: spacing and shielding of the contacts. For example, the contact points or bands may be spaced 1-2 diameters of the vagus nerve apart, and it may be helpful to shield current from these contacts from other nearby structures susceptible to inadvertent triggering. The cuff may be further optimized by using bands which are as long and wide as possible to reduce neurostimulator power requirements.
Thus, any variations of the systems described herein (e.g., the NCAP system) may be implemented with a Cuff, Lead and Implantable Pulse Generation (IPG), or a Leadless Cuff. The preferred implementation is a leadless cuff implemented by a microstimulator with integral electrode contacts in intimate contact with the nerve and contained within a Protection and Orientation Device (POD). This is illustrated in
Referring back to
As described in more detail in U.S. Ser. No. 12/874,171 (titled “PRESCRIPTION PAD FOR TREATMENT OF INFLAMMATORY DISORDERS”), previously incorporated by reference in its entirety, the Prescription Pad may incorporate workflows in a simplified interface and provide data collection facilities that can be transferred to an external database utilizing commercially robust and compliant methods and procedures. In use, the system may be recommended for use by a clinician after assessing a patient; the clinician may determine that treatment of chronic inflammation is warranted. The clinician may then refer the patient to an interventional doctor to implant the microstimulator. Thereafter then clinician (or another clinician) may monitor the patient and adjust the device via a wireless programmer (e.g. prescription pad). The clinician may be trained in the diagnosis and treatment procedures for autoimmune and inflammatory disorders; the interventional placement of the system may be performed by a surgeon trained in the implantation of active neurostimulation devices, with a sufficient depth of knowledge and experience regarding cervical and vagal anatomy, experienced in performing surgical dissections in and around the carotid sheath.
The system may output signals, including diagnostics, historical treatment schedules, or the like. The clinician may adjust the device during flares and/or during routine visits. Examples of implantation of the microstimulator were provided in U.S. Ser. No. 12/874,171. For example, the implant may be inserted by making an incision in the skin (e.g., ≈3 cm) along Lange's crease between the Facial Vein and the Omohyoid muscle, reflecting the Sternocleidomastoid and gaining access to the carotid sheath. The IJV may be displaced, and the vagus may be dissected from the carotid wall (≤2 cm). A sizing tool may be used to measure the vagus, and an appropriate Microstimulator and POD Kit (small, medium, large) may be selected. The POD may then be inserted under nerve with the POD opening facing the surgeon, so that the microstimulator can be inserted inside POD so that the microstimulator contacts capture the vagus. The POD may then be sutured shut. In some variations a Surgical Tester may be used to activate the microstimulator and perform system integrity and impedance checks, and shut the microstimulator off, during or after the implantation. In other variations the surgical tester may be unnecessary, as described in greater detail below.
A physician may use the Patient Charger to activate the microstimulator, perform integrity checks, and assure sufficient battery reserve exists. Electrodes may be conditioned with sub-threshold current and impedances may be measured. A Physician may charge the microstimulator. In some variations a separate charger (e.g., an “energizer”) may be used by the patient directly, separate from the controller the physician may use. Alternatively, the patient controller may include controls for operation by a physician; the system may lock out non-physicians (e.g., those not having a key, code, or other security pass) from operating or modifying the controls.
In general, a physician may establish safe dosage levels. The physician may slowly increment current level to establish a maximum limit (Upper Comfort Limit). This current level may be used to set the Dosage Level. The exact procedure may be determined during this clinical phase.
The Physician may also specify dosing parameters that specify dosage levels and dosage intervals. The device may contain several concurrent dosing programs which may be used to acclimate the patient to stimulus, gradually increase dosage until efficacy is achieved, reset tachyphylaxis, or deal with unique patient situations.
As mentioned, a patient may use the Patient Charger to replenish the microstimulator battery at necessary times (e.g., every day, every week, etc.). A clinician may also work with the patient to setup a schedule based upon the patient's stimulation needs and lifestyle. In some variations, the microstimulator battery charging is achieved by expanding the Patient Charger loop, putting the loop over the head, and closing the handle to close the loop, which may position the charger sufficiently near the implanted device. Charging may start automatically or the user (patient or physician) can push a charge button. The patient may watch the progress on the Patient Charger and may be signaled when charging is complete. The length of the charge may depend primarily upon dosage level. The more often a patient charges, the shorter the charge time may be.
The charger and/or implant may include a clock, and in some variations the patient may set the time zone on the Patient Charger to reflect his/her location. The Patient Charger may update the microstimulator time parameters while charging. This may enable the patient to adjust for travel related time zone changes or daylight savings time adjustments. Because stimulation may be perceptible (felt by the patient), it may be important that the patient receive the stimulation at the same time(s) every day.
If the patient does not charge frequently enough, the system may automatically cease treatment when about 3 months of standby battery remains. Once treatment stops the patient must visit their physician to restart treatment, to avoid damage to the implant requiring re-implantation.
In general, the microstimulator and POD can be suitable for chronic treatment with a design life of 10 years or more. The battery may support a 20 year life. Microstimulator battery charging intervals may be dependent on patient dose settings, however, as described in greater detail below, the system may be configured to conserve power and therefore minimize charging intervals and/or times, greatly enhancing patient comfort and compliance.
The microstimulator and POD may be packaged into kits. Any of the systems described herein may also include a surgical kit with the items necessary for the implantation of Microstimulator and POD. This does not prevent the surgeon, during a revision, from using the existing POD and only replacing the microstimulator. System kits may be available for small, medium, and large vagus nerves. A vagus nerve sizing kit may be available to determine which kit to use. In some variations the microstimulator and POD have a loose fit such the lumen of the device and the widest part of the nerve has a loose fit without constraining blood flow, and allowing axial flexibility and both compressive and tensile forces on the device without damaging the nerve. For example, the POD may encapsulate the microstimulator so current leakage may occur through vagus nerve access ports. All other sources of current leakage may be <25 uA when POD is sutured shut. The microstimulator may have a slot for the vagus nerve. This slot may have three sizes (approximately small, medium, large) for vagus nerves of approximately (e.g., +/−5%, 10%, 20%, 30%, 40%, 50%): 2 w×1.5 h; 3 w×2 h; 4 w×3 h (mm).
Implantable components of the microstimulator and POD and components are typically applied within the sterile barrier during the interventional procedure and may be supplied sterile. Sterilization method may be Ethylene Oxide (EO).
In some variations, the POD may be secured by 1-3 sutures and may include a marker to easily allow surgeon to match suture holes minimizing failure. The POD may be configured so that over-tightening the sutures does not cause vagal devascularization. The microstimulator and POD cross sectional area may not exceed 60 mm2 including the largest nerve model. The volume including the largest nerve model may be less than 1.5 cc.
Because rotation around the axis and movement up and down on the vagus nerve may occur during the healing period. The Patient Charger may allow accommodation of this movement.
In some variations, the microstimulator may have a bipolar stimulation current source that produce as stimulation dose with the characteristics shown in table 1, below. In some variation, the system may be configured to allow adjustment of the “Advanced Parameters” listed below; in some variations the parameters may be configured so that they are predetermined or pre-set. In some variations, the Advanced Parameters are not adjustable (or shown) to the clinician. All parameters listed in Table 1 are ±5% unless specified otherwise.
The Dosage Interval is defined as the time between Stimulation Doses. In some variations, to support more advanced dosing scenarios, up to four ‘programs’ can run sequentially. Each program has a start date and time and will run until the next program starts. Dosing may be suspended while the Prescription Pad is in Programming Mode. Dosing may typically continue as normal while charging. Programs may be loaded into one of four available slots and can be tested before they start running. Low, Typical, and High Dose schedules may be provided. A continuous application schedule may be available by charging every day, or at some other predetermined charging interval. For example, Table 2 illustrates exemplary properties for low, typical and high dose charging intervals:
The system may also be configured to limit the leakage and maximum and minimum charge densities, to protect the patient, as shown in Table 3:
In some variations, the system may also be configured to allow the following functions (listed in Table 4, below):
As mentioned above, in some variations, the system may record function of the microstimulator (e.g., a limited patient history). For example, the system may record: date and time that each program that is started and the associated program parameters; power down events due undercharging; hardware or software exceptions; emergency power down events; compliance events with associated impedance measurement; etc. In some variations, at least the last 50 events may be preserved in a circular buffer. Any of the systems describe herein may be approved for MRI usage at 3 Tesla (e.g., the torque will be less than a maximum threshold, the temperature rise may be less than 4° C., and the blackout area may be less than a maximum threshold volume. In some variations, the microstimulator and POD may be configured to withstand monopolar electrocautery.
The Patient Charger (including the energizer variations) typically fits over a patient's head to charge the implants in the patient's neck. As described in greater detail below, the Patient Charger may support neck circumferences ranging between 28-48 cm and head circumferences of up to 72 cm. The implant and the charger may further be configured so that they orientation of the charger and implant may allow sufficient tolerance to permit charging when worn by the user in a number of positions, without requiring substantial repositioning. The Patient Charger may provide functionality that can be accessed through a connected Prescription Pad or other external controller. For example, Table 5 below lists some function elements that may be accessed by a prescription pad in conjunction with a charger:
In general, a charger (which may be used by a patient directly) may include a recharge reminder alarm (audio and/or visual) that will remind the patient to charger on a daily, weekly, or monthly frequency. The Patient Charger may be charged through a Wall Adapter plug alone or in conjunction with a Charging Dock. The Patient Charger may clearly indicate that it is charging.
In some variations, the Patient Charger firmware will be version controlled and may be updated with Prescription Pad software in the field, or can be updated in the factory. For example, the Prescription Pad software may be controlled and may be updated in the field by the one or more web applications, a USB Dongle, a CD, etc. In some variations, the Prescription Pad may identify the microstimulator through a unique electronic ID electronically available in the microstimulator. The ID may be linked to a serial number that is embossed in the case. However, the Patient Charger may not require knowledge of this ID to charge the device.
The microstimulators described herein are configured for implantation and stimulation of the cholinergic anti-inflammatory pathway, and especially the vagus nerve. In particular the microstimulators described herein are configured for implantation in the cervical region of the vagus nerve to provide extremely low duty-cycle stimulation sufficient to modulate inflammation. These microstimulators may be adapted for this purpose by including one or more of the following characteristics, which are described in greater detail herein: the conductive capsule ends of the microstimulator may be routed to separate electrodes; the conductive capsule ends may be made from resistive titanium alloy to reduce magnetic field absorption; the electrodes may be positioned in a polymer saddle; the device includes a suspension (e.g., components may be suspended by metal clips) to safeguard the electronics from mechanical forces and shock; the device may include an H-bridge current source with capacitor isolation on both leads; the device may include a built in temperature sensor that stops energy absorption from any RF source by detuning the resonator; the device may include a built-in overvoltage sensor to stop energy absorption from any RF source by detuning resonator; the system may include DACs that are used to calibrate silicon for battery charging and protection; the system may include DACs that are used to calibrate silicon for precision timing rather than relying on crystal oscillator; the system may include a load stabilizer that maintains constant load so that inductive system can communicate efficiently; the system may include current limiters to prevent a current rush so that the microstimulator will power up smoothly from resonator power source; the system may extract a clock from carrier OR from internal clock; the device may use an ultra low power accurate RC oscillator that uses stable temperature in body, DAC calibration, and clock adjustment during charging process; the device may use a solid state LIPON battery that allows fast recharge, supports many cycles, cannot explode, and is easy to charge with constant voltage; and the device may include a resonator that uses low frequency material designed not to absorb energy by high frequency sources such as MRI and Diathermy devices.
Many of these improvements permit the device to have an extremely small footprint and power consumption, while still effectively modulating the vagus nerve.
As mentioned above, some of the device variations described herein may be used with a POD to secure the implant (e.g., the leadless/wireless microstimulator implant) in position within the cervical region of the vagus nerve so that the device may be programmed and recharged by the charger/programmer (e.g., “energizer”). For example,
In many variations, the microstimulators described herein are tunable electrical nerve stimulators configured to deliver modulated electrical stimulus to the vagus nerve of the patient for treatment of inflammatory and autoimmune disorders. The microstimulator, in conjunction with the POD, is intended to perform as a chronic stimulating unit that generates output pulses with defined electrical characteristics to the vagus nerve of a patient. The stimulator is intended for chronic use and may be capable of executing patient specific programs with varying parameters in order to treat a wide array of diseases with differing severity levels.
In some variations, including those described above, the microstimulator consists of a ceramic body with hermetically sealed titanium-niobium ends and integral platinum-iridium electrodes attached. The microstimulator may be designed to fit within a POD 309, as shown in
In general, the microstimulator is designed to be implanted within deep tissue, so that it can be recharged and controlled using an external (e.g., transcutaneous) inductive link through a charger encircling the implant outside the body. One advantage to the microstimulators configured as described herein (including the extremely low duty-cycle of the device) is the low energy requirements of these devices, particularly as compared to prior art devices. For example, Table 6, below illustrates exemplary charging and use profiles for low, typical and maximally used implants. In general, the daily charging duration for low and average patients may be less than 2 minutes/day, and for Maximum patients less than 10 minutes per day.
The electrode of the microstimulator may provide a nerve contact area equal to approximately ½ the surface area of the nerve for at least a length of 5 mm. Minimum electrode area=2 mm (min vagus diameter)×π×5 mm (min length)×½ circumference=15 mm2. For example, a vagus nerve diameter of 2-4 mm may be supported. In combination with the POD, less than 1 mm of total gap may be allowed around the vagus, indicating three sizes or adjustable electrodes. The bipolar Impedances of the electrodes may be less than 1000 ohms (real component).
In some variations (such as the variation illustrated above in
The Patient Charger communicates with and replenishes the microstimulator deep within the body (e.g., neck) utilizing an electromagnetic field. The Patient Charger may be used by both clinicians and patients. It may include a coil that is run through a handle that separates to expand for placement over then head. Once placed over the head and closed the Patient Charger may attempt to find the Microstimulator and start charging. When charging is complete the patient may be signaled. In use, a clinician may program the microstimulator by connecting a USB cable between the Prescription Pad and the Patient Charger. The Patient Charger wirelessly connect with the implant and with outer devices (e.g., the controller such as a prescription pad). The Patient Charger may also record all charging sessions and store Microstimulator data.
The chargers described herein are configured and optimized for use with the cervical, low duty-cycle microstimulators described above, or for sub-diaphragmatic use. These charges may be worn about a subject's neck and/or waist (or torso) and may very quickly charge the implanted microstimulator, and may program and control the microstimulator as well as receive data or information from the microstimulator. The chargers described herein may use a solenoid that connects around the subject's neck with novel connection mechanism. For example, the connection mechanism may be clasp or quick connect connector that connects the loop (coil) of the charger around the subject's neck. The quick connector may be magnetic or friction fit. For example, in some variations the connector closing the loop around the subject's neck includes insertion of pins to connect one side of the loop(s) with the opposite side. For example, in some variations, the charger (e.g., energizer) coil uses a breakable coil with a magnetic latch and pogo spring pins to make contact. The coil resistance may be kept low despite the clasp/connection. For example, a multiplicity of pins may be used to keep coil resistance low and Q high.
The magnetic field strength of the charger may be modulated via a digitally compensated pwm circuit so that the power is critically tuned rather than using a resistive element. In addition, the carrier frequency may be generated using a phase accumulator to provide highly accurate frequency generation for precise tuning.
The Patient Charger may be stored in a Charging Dock to keep the battery in a charged state. A travel wall socket adapter may also be used. The Charger typically includes a battery, such as a LION rechargeable battery.
In operation, the Patient Charger may develop an axial magnetic field in alignment with the Microstimulator in the neck. The loop is sized to accommodate the largest neck and provide sufficient power to charge the battery in the adjustments to assure that sufficient charge is being transferred to Microstimulator.
Recharge time for the Microstimulator may be dependent on how much energy is drained between recharges by the patient. This may depend upon the patient settings and how often the patient charges. Patients may be able to charge as infrequently as every month. This may allow the clinician to recommend a charging schedule that is most convenient for the patient; such as when a care giver is available. The neck loop makes charging a hands free operation once the device is put around the neck.
The Energizer and Microstimulator coils may be tuned to resonate so that energy is transferred with the maximum efficiency from the Energizer to Microstimulator. The Microstimulator in turn may harvest the energy from the Energizer created magnetic field to power itself. The power harvested may be less than 15 mW. Tuning, or maximizing the mutual inductance between the two coils may be performed by using resonators that are physically adjusted to approximately 133 KHz±4 KHz. Fine tune adjustments may be made dynamically by varying the Energizer frequency with the allocated 127-135 KHz frequency band. Another method to be employed for electronic tuning that may be used induces a static flux in series inductor in the Energizer coil to electronically modify the inductance (see, e.g., U.S. Pat. No. 3,631,534).
Energy transfer may be controlled by throttling the magnetic field. The magnetic field may be created by a high efficiency Class-D amplifier. The induced coil voltage on the resonator is controlled by the collector voltage driving the amplifier. It is important to only provide sufficient power to the implant as not to saturate the Microstimulator circuits or overheat the Microstimulator, a condition which can easily be achieved. Energy transfer varies significantly with vertical position so feedback is required. Feedback may be obtained by sending a query to the Microstimulator telemeter incoming energy level. This feedback may also be obtained by measuring the difference in Energizer coil voltage between the presence and absence of the Microstimulator, as described herein. With that measure the energy being absorbed by the Microstimulator can be calculated with sufficient accuracy to control the Energizer collector voltage.
The telemetry system in this example is implemented such that two standard microprocessor UARTs communication with a RS-232 type half duplex protocol where the Energizer is the master. Two rates, e.g., 1200 and 4800 baud, may be implemented. Forward telemetry modulates the transmitter collector voltage to send data across. To keep the Microstimulator demodulator as simple as possible a DC balanced Manchester code may be employed with a simple zero crossing data slicer. The RS-232 code itself does not need to be DC balanced, but the presence of start and stop bits are sufficient to allow sufficient energy transfer during communications.
The Microstimulator resonated may be put into one of two states with a shorting switch. When the switch is open the Microstimulator is operating normally, receiving power and telemetry, and is loading the Energizer. When the Microstimulator switch is closed the coil is no longer tuned to the Energizer coil and the Microstimulator ceases to receive power, and the load that the Microstimulator normally asserts on the Energizer is removed. This switch provides several functions: it may be used to send back telemetry data to the Energizer, used by the Energizer to measure the power absorption by the Microstimulator, and/or used by the Microstimulator to turn off power absorption in case the Microstimulator becomes too hot or the internal voltage becomes too high.
The Microstimulator may respond to all packets by toggling the load switch with the UART. Data is sent in NRZ format (e.g., back telemetry). The Energizer may measure the coil voltage, removing the ≈130 KHz carrier and extracting the resulting data stream that is effectively the peak coil voltage updated at a rate of 20 KHz. The Energizer converts this analog voltage into a digital word and slices the data to produce bits that are fed to the UART. This is done in the digital domain because a sophisticated min/max peak detector can be implemented that does not require DC balanced data and can respond within 1-2 symbols.
Power is adjusted by achieving a target modulation depth on received back telemetry data. The target modulation depth is determined by calibrating the system through measurements of power transfer to the Microstimulator. It is unknown at this point when calibration will occur: once for all systems, once for each system, on power up of each system, continuously as the Energizer coil moves around.
Static Magnetic Field Detector
Any of the implantable microstimulators described herein can include a static magnetic field detector for emergency shut off of the microstimulator. Though many safety measures have been taken, there might be unexpected situations such as circuit dysfunction or failure, sudden health condition change of the patient, unusual environment, thermistor failure, etc. A manual shut-off of the microstimulator may be needed in such emergency situations. In some variations, a magnet can be placed near the implantable microstimulator to trigger the static magnetic field detector and cause an emergency shutdown of the microstimulator.
The static magnetic field detector can comprise a low power pulse generator. For example, a low power current pulse generator can be connected with the RLC circuit. In some variations, the power of the pulse generator can be lower than 10 microwatts. For example, the pulse generator can be an ultra-low power pulse generator based on a ring oscillator with the power between 1 nanowatt and 10 microwatts. In some other variations, the power of the pulse generator can be between 1 nanowatt and 1 microwatt. In yet some other variations, the power of the pulse generator can be lower than 1 nanowatt.
As shown, the low power pulse from the pulse generator can be introduced into the coil or the resonator RLC circuit. As known to the skilled in the art, RLC circuit can resonate at a resonance frequency or a predetermined frequency range. The oscillating current pulses decay with time due to the resistance in the circuit. When the coil is tuned, the low power pulses can take a relatively long time to decay. But when a magnetic field is introduced to the coil, the inductance of the RLC circuit is changed and the coil is detuned. Therefore, the decay rate is much quicker (or time constant is smaller). For example, a magnet can be placed near the implantable microstimulator, the ferrite of the coil can be coupled with the inductance of the static magnetic field of the magnet, the inductance of the RLC resonator can be changed to be off the resonance frequency or the predetermined frequency range. When the coil is detuned, the low power pulses take a much faster time to drop off to zero. The decay rate of the pulses can be much higher.
The static magnetic field detector can further comprise a detection circuit as shown in
The static magnetic field detector can be configured to shut down the microstimulator in a variety of ways. For example, the static magnetic field detector can be configured to shut down the microstimulator by using h a shorting switch. In some variations, when the switch is open, the microstimulator is operating normally; when the switch is closed, the resonator is open and the microstimulator turns off power. In some other variations, when the switch is closed, the microstimulator is operating normally; when the switch is open, the microstimulator turns off power.
In some variations, the low power pulses (e.g., from pulse generator 505) can be introduced periodically, such as every second, to detect the presence of the magnetic field. In some other variations, the low pulses can be introduced continuously to constantly monitoring the presence of the magnetic field.
Disclosed herein are also methods to shut down an implantable microstimulator by using a static magnetic field. In some variations, the method of shutting down an implantable microstimulator by the static magnetic field detector can comprise utilizing a built-in receiving coil of the microstimulator. In some other variations, the method of shutting down an implantable microstimulator by the static magnetic field detector can comprise utilizing another RLC resonator of the microstimulator.
The method of shutting down an implantable microstimulator by a static magnetic field detector can further comprise introduce the pulses into the coil of the RLC resonator 603. For example, the pulses can be current pulses connected to the RLC resonator. The method can further comprise placing a magnet near the implantable microstimulator 605.
The method of shutting down an implantable microstimulator by a static magnetic field detector can further comprise monitoring the decay rate of the pulses of the resonator or the time constant of the RLC resonator 607, and determine if they are increasing or decreasing 609. When the coil is tuned, the low power pulses can take a relatively long time to decay. But when a magnetic field is introduced to the coil, the inductance of the RLC circuit is changed and the coil is detuned. Therefore, the decay rate can be much larger (or time constant can be smaller). The static magnetic field detector can be configured to shut down the microstimulator when the decay rate is at a predetermined value 611, for example, the decay rate is 1.5, 2, 2.5, 3, 4, 5, 10 times of the previous value or any values therebetween. Values outside the above range are also possible. Shutting down the device may immediately stop delivery of power to the nerve to which the implant is attached.
Any appropriate static magnetic field sensor may be used, although it may be particularly beneficial to avoid Hall effect devices. In addition to the use of a low-power pulse applied to the resonator and a detection circuit, as described above, in any of these apparatuses a Wiegand material may be used, or any other material that uses a magnetic hysteresis effect. The Wiegand effect is a nonlinear magnetic effect, and may include the use of a specially annealed and hardened wire (“Wiegand wire”), such as a low-carbon Vicalloy, a ferromagnetic alloy of cobalt, iron, and vanadium. The wire may exhibits a very large magnetic hysteresis: if a magnet is brought near the wire, the high coercivity outer shell excludes the magnetic field from the inner soft core until the magnetic threshold is reached, whereupon the entire wire—both the outer shell and inner core may rapidly switch magnetization polarity (the Wiegand effect). The voltage induced by a changing magnetic field may be proportional to the rate of change of the field, thus a Wiegand-wire core can increase the output voltage of a magnetic field sensor by several orders of magnitude as compared to a similar coil with a non-Wiegand core. This higher voltage can easily be detected electronically.
Power Control Loop
As mentioned above, in any of these apparatuses, in order to protect the patient from harm from overheating of the neurostimulator, the temperature of the outer surface of the implant can be kept within a minimum temperature range (e.g., <1.1° C., 1.3° C., 1.5° C., 1.7° C., 1.8° C., 1.9° C., 2° C., 2.1° C., 2.2° C., 2.3° C., 2.4° C., 2.5° C., etc.) of the normal surrounding body temperature. This temperature of operation is particularly critical when the implant is interacting with the charger, as described above. As will be outlined herein, the temperature of the microstimulator may be regulated within a predetermined temperature range (e.g., within about 2 degrees Celsius) by controlling the power drawn by the microstimulator from the charger.
Although the temperature may be estimated by one or more thermistor within the implant that may be used to estimate temperature, and may detune the microstimulator coil when the internal temperature reaches a threshold (internal threshold, e.g., approximately 41.5° C.), the critical temperature may be the external temperature, rather than the internal temperature. Although it may be difficult to measure the outside temperature, accurate estimation of this temperature may allow more precise and longer-lasting control of the implant, including during charging and/or telemetry, as well as enhancing safety.
q=CiΔTi,
Where Ci is a lumped heat loss coefficient that characterizes the heat flux path through point i into the surrounding medium. Thus, in vitro measurements show that accurate estimates of surface temperature can be determine for given power levels. If the power in (PWRIN) can be regulated (e.g., below a threshold level) then the maximum surface temperature may be regulated to <2° C. different relative to body temperature (+/−2° C.).
In operation, the PWRIN can be determined by directly querying the microstimulator (also referred to herein as the microregulator or MR). For example, the charger can query the microstimulator during charging for the PWRIN, and can adjust the power level of the charger to ensure that PWRIN remains below the desired threshold (e.g., 16V or another predetermined voltage level). However, querying the microstimulator may require a communication link between the MR and the charger and software to process and handle this information. It would be desirable if the PWRIN, the tank voltage of the MR, could be determined by values that can be measured entirely on the charger.
For example,
M=k√{square root over (L1L2)},
k is the coupling coefficient. Rectifier circuit is represented as an ideal diode in this example (
Where RL is the load resistance and
V2=kQ2√{square root over (L1L2)}jωi1
It may be shown that the reflected impedance, ZT is given by:
Then:
|V1|=|i1(R1+jωL1+ZT)|,
or
|V1|=|V1unloaded|+|VT|,
where V1 unloaded corresponds to R×U and VT to R×U−R×l. Plotting V2=PWRN vs. margin (R×U−R×L) gives a different curve for each value of k, as shown in
Even for worst-case placement of the microstimulator, the apparatus may determine the value of T×Hmax that gives a target PWRIN (e.g., 16V in the examples above) to keep the temperature within a desired range. For example, for any value of T×H above T×Hmax, the implant may use duty cycling to keep the average power constant, as shown in
For example:
Based on this, the apparatus may determine, for a particular combination of implant and charger, a PWRIN that keeps the Tmax of the surface of the implant within a predetermined limit (e.g., +/−2° C.). In general, MR temperature is proportional to the square of PWRIN. PWRIN may be estimated based only on measurements of energizer coil voltage, and an energizer power control loop may be based on the parameter T×H(R×U−R×L) to maintain a relatively constant value of PWRIN regardless of implant location. When the implant (microstimulator) load modulation is not detected by the charger, duty-cycling may keep the Tmax within limit assuming the worst-case position of the microstimulator. The power control loop may be entirely hardware based, or can include firmware or software.
Thus, a target value for the power control parameter can be determined based on the type of charger, the type of implant, and the type of coupling between the two. The target values can be determined based on in vitro experiments, or can be determined in vivo during a calibration procedure. The above method of controlling the outer temperature of the MR works well except when the MR load modulation (R×U−R×L) is not detected. In this situation, the MR can be duty cycled to keep the temperature within limits, assuming the worst-case placement for MR placement, as shown in
As mentioned, a power negotiation protocol can be used by the charger and MR to determine what power level (e.g. T×H) or charge rate should be used to charge the MR. At the start of the protocol, the charging may be turned off or throttled and the communications between the charger and MR can be turned on. The initial communications can be used to exchange information regarding the type of charger (charger capabilities), the type of battery (implant capabilities), and the coupling used between the two devices, which can all be used to determine the appropriate charge rate or power level.
When the MS draws too much power, communications may collapse. Therefore, the power drawn by the MS can be throttled to restore communications. For example, in some embodiments, as the battery (e.g., a Quallion lithium-ion battery) charge is depleted, the charging current drawn from the RF tank circuit increases. This can cause antenna voltage of the implant to drop below the regulator drop out voltage in situations where insufficient RF power is available (e.g., when the implant is far from the external charger or separated from the charger by greater than a predetermined distance), which can cause communications to drop out.
In some embodiments, to mitigate this problem and prevent the antenna voltage from dropping below the regulator drop out voltage, the implant can use an adjustable current limit that restricts the amount of current drawn by the implant to perform functions outside of communication, such as charging the battery. When the implant initiates RF contact with the charger, the current limit of the implant is set to a predetermined minimum level, which presents a maximum load impedance to the RF tank circuit. If the antenna voltage of the implant is above a predetermined limit, the current limit of the implant may be increased to the next level by a predetermined amount. The process may be repeated until either the predetermined maximum current limit is reached, or the antenna voltage of the implant falls below the predetermined limit. If the antenna voltage of the implant falls below the predetermined limit, the current limit of the implant can be set at the previous level by decreasing the current limit by a predetermined amount.
One embodiment for adjusting the current in the implant is to provide the implant with a voltage controlled current source in the charging circuit as shown in
Prior art implants typically adjust the RF external power provided by the charger to meet the internal needs of the implant. In contrast, the implant described above is uniquely designed to modulate the power drawn by the implant, by throttling the current for example, given the RF external power provided by the charger. Such a configuration prioritizes communications over powering other functions of the implant, such as charging the battery, even though both functions may share the same circuit channel. Such a configuration also enables a “low power mode” which preserves communications even when the RF external power provided by the charger is relatively low.
Alternatively or additionally, an intermediate field communication link can be used instead of communicating through the power signal. The intermediate field communication link can be powered by the battery of the MR and use a high-gain amplifier to amplify the RF signal for transmission to the charger. This would allow the charger and MR to communicate at a longer range and enable more convenient pairing or initialization of the devices, such as before the charger is worn around the neck. For example, the patient can initiate communications while simply holding the charger in his hands, rather than having to wear the charger before initiating communications.
When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.
Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.
In general, any of the apparatuses and methods described herein should be understood to be inclusive, but all or a sub-set of the components and/or steps may alternatively be exclusive, and may be expressed as “consisting of” or alternatively “consisting essentially of” the various components, steps, sub-components or sub-steps.
As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “X” is disclosed the “less than or equal to X” as well as “greater than or equal to X” (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
Although various illustrative embodiments are described above, any of a number of changes may be made to various embodiments without departing from the scope of the invention as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. Optional features of various device and system embodiments may be included in some embodiments and not in others. Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the invention as it is set forth in the claims. The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.
This patent application claims priority to U.S. provisional patent application No. 62/286,951, titled “POWER CONTROL AND THERMAL REGULATION OF AN IMPLANTABLE NEURO STIMULATOR,” Filed on Jan. 25, 2016; U.S. provisional patent application No. 62/340,937, titled “POWER CONTROL AND THERMAL REGULATION OF AN IMPLANTABLE NEURO STIMULATOR,” filed on May 24, 2016; and U.S. provisional patent application No. 62/286,955, titled “IMPLANTABLE MICROSTIMULATORS,” filed on Jan. 25, 2016. Each of these patent applications is herein incorporated by reference in its entirety. This patent application may be related to U.S. patent application Ser. No. 14/887,192, titled “NEURAL STIMULATION DEVICES AND SYSTEMS FOR TREATMENT OF CHRONIC INFLAMMATION,” filed Oct. 19, 2015, which is a continuation of U.S. patent application Ser. No. 14/508,940, titled “NEURAL STIMULATION DEVICES AND SYSTEMS FOR TREATMENT OF CHRONIC INFLAMMATION,” filed Oct. 7, 2014, now U.S. Pat. No. 9,162,064, which is a continuation of U.S. patent application Ser. No. 14/082,047, titled “NEURAL STIMULATION DEVICES AND SYSTEMS FOR TREATMENT OF CHRONIC INFLAMMATION,” filed Nov. 15, 2013, now U.S. Pat. No. 8,855,767, which is a divisional of U.S. patent application Ser. No. 12/978,250, titled “NEURAL STIMULATION DEVICES AND SYSTEMS FOR TREATMENT OF CHRONIC INFLAMMATION,” filed on Dec. 23, 2010, now U.S. Pat. No. 8,612,002, which claims priority to U.S. Provisional Patent Application Nos. 61/289,946, titled “LEADLESS CUFF MICROSTIMULATOR STIMULATOR,” filed on Dec. 23, 2009; and 61/306,849, titled “NEURAL STIMULATION DEVICES AND SYSTEMS FOR TREATMENT OF CHRONIC INFLAMMATION,” filed on Feb. 22, 2010. Also incorporated by reference herein is: abandoned U.S. patent application Ser. No. 12/874,171, titled “PRESCRIPTION PAD FOR TREATMENT OF INFLAMMATORY DISORDERS” filed Sep. 1, 2010. Each of the above-mentioned applications are herein incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2164121 | Pescador | Jun 1939 | A |
3363623 | Atwell | Jan 1968 | A |
3631534 | Hirota et al. | Dec 1971 | A |
4073296 | McCall | Feb 1978 | A |
4098277 | Mendell | Jul 1978 | A |
4305402 | Katims | Dec 1981 | A |
4503863 | Katims | Mar 1985 | A |
4573481 | Bullara | Mar 1986 | A |
4590946 | Loeb | May 1986 | A |
4632095 | Libin | Dec 1986 | A |
4649936 | Ungar et al. | Mar 1987 | A |
4702254 | Zabara | Oct 1987 | A |
4840793 | Todd, III et al. | Jun 1989 | A |
4867164 | Zabara | Sep 1989 | A |
4929734 | Coughenour et al. | May 1990 | A |
4930516 | Alfano et al. | Jun 1990 | A |
4935234 | Todd, III et al. | Jun 1990 | A |
4979511 | Terry, Jr. | Dec 1990 | A |
4991578 | Cohen | Feb 1991 | A |
5019648 | Schlossman et al. | May 1991 | A |
5025807 | Zabara | Jun 1991 | A |
5038781 | Lynch | Aug 1991 | A |
5049659 | Cantor et al. | Sep 1991 | A |
5073560 | Wu et al. | Dec 1991 | A |
5106853 | Showell et al. | Apr 1992 | A |
5111815 | Mower | May 1992 | A |
5154172 | Terry, Jr. et al. | Oct 1992 | A |
5175166 | Dunbar et al. | Dec 1992 | A |
5179950 | Stanislaw | Jan 1993 | A |
5186170 | Varrichio et al. | Feb 1993 | A |
5188104 | Wernicke et al. | Feb 1993 | A |
5203326 | Collins | Apr 1993 | A |
5205285 | Baker, Jr. | Apr 1993 | A |
5215086 | Terry, Jr. et al. | Jun 1993 | A |
5215089 | Baker, Jr. | Jun 1993 | A |
5222494 | Baker, Jr. | Jun 1993 | A |
5231988 | Wernicke et al. | Aug 1993 | A |
5235980 | Varrichio et al. | Aug 1993 | A |
5237991 | Baker et al. | Aug 1993 | A |
5251634 | Weinberg | Oct 1993 | A |
5263480 | Wernicke et al. | Nov 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5299569 | Wernicke et al. | Apr 1994 | A |
5304206 | Baker, Jr. et al. | Apr 1994 | A |
5330507 | Schwartz | Jul 1994 | A |
5330515 | Rutecki et al. | Jul 1994 | A |
5335657 | Terry, Jr. et al. | Aug 1994 | A |
5344438 | Testerman et al. | Sep 1994 | A |
5351394 | Weinberg | Oct 1994 | A |
5403845 | Dunbar et al. | Apr 1995 | A |
5458625 | Kendall | Oct 1995 | A |
5472841 | Jayasena et al. | Dec 1995 | A |
5487756 | Kallesoe et al. | Jan 1996 | A |
5496938 | Gold et al. | Mar 1996 | A |
5503978 | Schneider et al. | Apr 1996 | A |
5531778 | Maschino et al. | Jul 1996 | A |
5540730 | Terry, Jr. et al. | Jul 1996 | A |
5540734 | Zabara | Jul 1996 | A |
5567588 | Gold et al. | Oct 1996 | A |
5567724 | Kelleher et al. | Oct 1996 | A |
5571150 | Wernicke et al. | Nov 1996 | A |
5580737 | Polisky et al. | Dec 1996 | A |
5582981 | Toole et al. | Dec 1996 | A |
5604231 | Smith et al. | Feb 1997 | A |
5607459 | Paul et al. | Mar 1997 | A |
5611350 | John | Mar 1997 | A |
5618818 | Ojo et al. | Apr 1997 | A |
5629285 | Black et al. | May 1997 | A |
5637459 | Burke et al. | Jun 1997 | A |
5651378 | Matheny et al. | Jul 1997 | A |
5654151 | Allen et al. | Aug 1997 | A |
5683867 | Biesecker et al. | Nov 1997 | A |
5690681 | Geddes et al. | Nov 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5705337 | Gold et al. | Jan 1998 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5709853 | Lino et al. | Jan 1998 | A |
5712375 | Jensen et al. | Jan 1998 | A |
5718912 | Thompson et al. | Feb 1998 | A |
5726017 | Lochrie et al. | Mar 1998 | A |
5726179 | Messer, Jr. et al. | Mar 1998 | A |
5727556 | Weth et al. | Mar 1998 | A |
5733255 | Dinh et al. | Mar 1998 | A |
5741802 | Kem et al. | Apr 1998 | A |
5773598 | Burke et al. | Jun 1998 | A |
5786462 | Schneider et al. | Jul 1998 | A |
5788656 | Mino | Aug 1998 | A |
5792210 | Wamubu et al. | Aug 1998 | A |
5824027 | Hoffer et al. | Oct 1998 | A |
5853005 | Scanlon | Dec 1998 | A |
5854289 | Bianchi et al. | Dec 1998 | A |
5902814 | Gordon et al. | May 1999 | A |
5913876 | Taylor et al. | Jun 1999 | A |
5916239 | Geddes et al. | Jun 1999 | A |
5919216 | Houben et al. | Jul 1999 | A |
5928272 | Adkins et al. | Jul 1999 | A |
5964794 | Bolz et al. | Oct 1999 | A |
5977144 | Meyer et al. | Nov 1999 | A |
5994330 | El Khoury | Nov 1999 | A |
6002964 | Feler et al. | Dec 1999 | A |
6006134 | Hill et al. | Dec 1999 | A |
6017891 | Eibl et al. | Jan 2000 | A |
6028186 | Tasset et al. | Feb 2000 | A |
6051017 | Loeb et al. | Apr 2000 | A |
6083696 | Biesecker et al. | Jul 2000 | A |
6083905 | Voorberg et al. | Jul 2000 | A |
6096728 | Collins et al. | Aug 2000 | A |
6104956 | Naritoku et al. | Aug 2000 | A |
6110900 | Gold et al. | Aug 2000 | A |
6110914 | Phillips et al. | Aug 2000 | A |
6117837 | Tracey et al. | Sep 2000 | A |
6124449 | Gold et al. | Sep 2000 | A |
6127119 | Stephens et al. | Oct 2000 | A |
6140490 | Biesecker et al. | Oct 2000 | A |
6141590 | Renirie et al. | Oct 2000 | A |
6147204 | Gold et al. | Nov 2000 | A |
6159145 | Satoh | Dec 2000 | A |
6164284 | Schulman et al. | Dec 2000 | A |
6166048 | Bencherif | Dec 2000 | A |
6168778 | Janjic et al. | Jan 2001 | B1 |
6171795 | Korman et al. | Jan 2001 | B1 |
6205359 | Boveja | Mar 2001 | B1 |
6208894 | Schulman et al. | Mar 2001 | B1 |
6208902 | Boveja | Mar 2001 | B1 |
6210321 | Di Mino et al. | Apr 2001 | B1 |
6224862 | Turecek et al. | May 2001 | B1 |
6233488 | Hess | May 2001 | B1 |
6266564 | Hill et al. | Jul 2001 | B1 |
6269270 | Boveja | Jul 2001 | B1 |
6304775 | Lasemidis et al. | Oct 2001 | B1 |
6308104 | Taylor et al. | Oct 2001 | B1 |
6337997 | Rise | Jan 2002 | B1 |
6339725 | Naritoku et al. | Jan 2002 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6356787 | Rezai et al. | Mar 2002 | B1 |
6356788 | Boveja | Mar 2002 | B2 |
6381499 | Taylor et al. | Apr 2002 | B1 |
6405732 | Edwards et al. | Jun 2002 | B1 |
6407095 | Lochead et al. | Jun 2002 | B1 |
6428484 | Battmer et al. | Aug 2002 | B1 |
6429217 | Puskas | Aug 2002 | B1 |
6447443 | Keogh et al. | Sep 2002 | B1 |
6449507 | Hill et al. | Sep 2002 | B1 |
6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
6479523 | Puskas | Nov 2002 | B1 |
6487446 | Hill et al. | Nov 2002 | B1 |
6511500 | Rahme | Jan 2003 | B1 |
6528529 | Brann et al. | Mar 2003 | B1 |
6532388 | Hill et al. | Mar 2003 | B1 |
6542774 | Hill et al. | Apr 2003 | B2 |
6556868 | Naritoku et al. | Apr 2003 | B2 |
6564102 | Boveja | May 2003 | B1 |
6587719 | Barrett et al. | Jul 2003 | B1 |
6587727 | Osorio et al. | Jul 2003 | B2 |
6600956 | Maschino et al. | Jul 2003 | B2 |
6602891 | Messer et al. | Aug 2003 | B2 |
6609025 | Barrett et al. | Aug 2003 | B2 |
6610713 | Tracey | Aug 2003 | B2 |
6611715 | Boveja | Aug 2003 | B1 |
6615081 | Boveja | Sep 2003 | B1 |
6615085 | Boveja | Sep 2003 | B1 |
6622038 | Barrett et al. | Sep 2003 | B2 |
6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
6622047 | Barrett et al. | Sep 2003 | B2 |
6628987 | Hill et al. | Sep 2003 | B1 |
6633779 | Schuler et al. | Oct 2003 | B1 |
6656960 | Puskas | Dec 2003 | B2 |
6668191 | Boveja | Dec 2003 | B1 |
6671556 | Osorio et al. | Dec 2003 | B2 |
6684105 | Cohen et al. | Jan 2004 | B2 |
6690973 | Hill et al. | Feb 2004 | B2 |
6718208 | Hill et al. | Apr 2004 | B2 |
6721603 | Zabara et al. | Apr 2004 | B2 |
6735471 | Hill et al. | May 2004 | B2 |
6735475 | Whitehurst et al. | May 2004 | B1 |
6760626 | Boveja | Jul 2004 | B1 |
6778854 | Puskas | Aug 2004 | B2 |
6804558 | Haller et al. | Oct 2004 | B2 |
RE38654 | Hill et al. | Nov 2004 | E |
6826428 | Chen et al. | Nov 2004 | B1 |
6832114 | Whitehurst et al. | Dec 2004 | B1 |
6838471 | Tracey | Jan 2005 | B2 |
RE38705 | Hill et al. | Feb 2005 | E |
6879859 | Boveja | Apr 2005 | B1 |
6885888 | Rezai | Apr 2005 | B2 |
6901294 | Whitehurst et al. | May 2005 | B1 |
6904318 | Hill et al. | Jun 2005 | B2 |
6920357 | Osorio et al. | Jul 2005 | B2 |
6928320 | King | Aug 2005 | B2 |
6934583 | Weinberg et al. | Aug 2005 | B2 |
6937903 | Schuler et al. | Aug 2005 | B2 |
6961618 | Osorio et al. | Nov 2005 | B2 |
6978787 | Broniatowski | Dec 2005 | B1 |
7011638 | Schuler et al. | Mar 2006 | B2 |
7054686 | MacDonald | May 2006 | B2 |
7054692 | Whitehurst et al. | May 2006 | B1 |
7058447 | Hill et al. | Jun 2006 | B2 |
7062320 | Ehlinger, Jr. | Jun 2006 | B2 |
7069082 | Lindenthaler | Jun 2006 | B2 |
7072720 | Puskas | Jul 2006 | B2 |
7076307 | Boveja et al. | Jul 2006 | B2 |
7142910 | Puskas | Nov 2006 | B2 |
7142917 | Fukui | Nov 2006 | B2 |
7149574 | Yun et al. | Dec 2006 | B2 |
7155279 | Whitehurst et al. | Dec 2006 | B2 |
7155284 | Whitehurst et al. | Dec 2006 | B1 |
7167750 | Knudson et al. | Jan 2007 | B2 |
7167751 | Whitehurst et al. | Jan 2007 | B1 |
7174218 | Kuzma | Feb 2007 | B1 |
7184828 | Hill et al. | Feb 2007 | B2 |
7184829 | Hill et al. | Feb 2007 | B2 |
7191012 | Boveja et al. | Mar 2007 | B2 |
7204815 | Connor | Apr 2007 | B2 |
7209787 | DiLorenzo | Apr 2007 | B2 |
7225019 | Jahns et al. | May 2007 | B2 |
7228167 | Kara et al. | Jun 2007 | B2 |
7238715 | Tracey et al. | Jul 2007 | B2 |
7242984 | DiLorenzo | Jul 2007 | B2 |
7269457 | Shafer et al. | Sep 2007 | B2 |
7345178 | Nunes et al. | Mar 2008 | B2 |
7389145 | Kilgore et al. | Jun 2008 | B2 |
7467016 | Colborn | Dec 2008 | B2 |
7544497 | Sinclair et al. | Jun 2009 | B2 |
7561918 | Armstrong et al. | Jul 2009 | B2 |
7711432 | Thimineur et al. | May 2010 | B2 |
7729760 | Patel et al. | Jun 2010 | B2 |
7751891 | Armstrong et al. | Jul 2010 | B2 |
7776326 | Milbrandt et al. | Aug 2010 | B2 |
7797058 | Mrva et al. | Sep 2010 | B2 |
7819883 | Westlund et al. | Oct 2010 | B2 |
7822486 | Foster et al. | Oct 2010 | B2 |
7829556 | Bemis et al. | Nov 2010 | B2 |
7869885 | Begnaud et al. | Jan 2011 | B2 |
7937145 | Dobak | May 2011 | B2 |
7962220 | Kolafa et al. | Jun 2011 | B2 |
7974701 | Armstrong | Jul 2011 | B2 |
7974707 | Inman | Jul 2011 | B2 |
7996088 | Marrosu et al. | Aug 2011 | B2 |
7996092 | Mrva et al. | Aug 2011 | B2 |
8019419 | Panescu et al. | Sep 2011 | B1 |
8060208 | Kilgore et al. | Nov 2011 | B2 |
8103349 | Donders et al. | Jan 2012 | B2 |
8165668 | Dacey, Jr. et al. | Apr 2012 | B2 |
8180446 | Dacey, Jr. et al. | May 2012 | B2 |
8180447 | Dacey et al. | May 2012 | B2 |
8195287 | Dacey, Jr. et al. | Jun 2012 | B2 |
8214056 | Hoffer et al. | Jul 2012 | B2 |
8233982 | Libbus | Jul 2012 | B2 |
8391970 | Tracey et al. | Mar 2013 | B2 |
8412338 | Faltys | Apr 2013 | B2 |
8571654 | Libbus et al. | Oct 2013 | B2 |
8577458 | Libbus et al. | Nov 2013 | B1 |
8600505 | Libbus et al. | Dec 2013 | B2 |
8612002 | Faltys et al. | Dec 2013 | B2 |
8630709 | Libbus et al. | Jan 2014 | B2 |
8688212 | Libbus et al. | Apr 2014 | B2 |
8700150 | Libbus et al. | Apr 2014 | B2 |
8729129 | Tracey et al. | May 2014 | B2 |
8788034 | Levine et al. | Jul 2014 | B2 |
8843210 | Simon et al. | Sep 2014 | B2 |
8855767 | Faltys et al. | Oct 2014 | B2 |
8886339 | Faltys et al. | Nov 2014 | B2 |
8914114 | Tracey et al. | Dec 2014 | B2 |
8918178 | Simon et al. | Dec 2014 | B2 |
8918191 | Libbus et al. | Dec 2014 | B2 |
8923964 | Libbus et al. | Dec 2014 | B2 |
8983628 | Simon et al. | Mar 2015 | B2 |
8983629 | Simon et al. | Mar 2015 | B2 |
8996116 | Faltys et al. | Mar 2015 | B2 |
9114262 | Libbus et al. | Aug 2015 | B2 |
9162064 | Faltys et al. | Oct 2015 | B2 |
9174041 | Faltys et al. | Nov 2015 | B2 |
9211409 | Tracey et al. | Dec 2015 | B2 |
9211410 | Levine et al. | Dec 2015 | B2 |
9254383 | Simon et al. | Feb 2016 | B2 |
9272143 | Libbus et al. | Mar 2016 | B2 |
9358381 | Simon et al. | Jun 2016 | B2 |
9399134 | Simon et al. | Jul 2016 | B2 |
9403001 | Simon et al. | Aug 2016 | B2 |
9409024 | KenKnight et al. | Aug 2016 | B2 |
9415224 | Libbus et al. | Aug 2016 | B2 |
9452290 | Libbus et al. | Sep 2016 | B2 |
9504832 | Libbus et al. | Nov 2016 | B2 |
9511228 | Amurthur et al. | Dec 2016 | B2 |
9533153 | Libbus et al. | Jan 2017 | B2 |
9572983 | Levine et al. | Feb 2017 | B2 |
20010002441 | Boveja | May 2001 | A1 |
20010034542 | Mann | Oct 2001 | A1 |
20020026141 | Houben et al. | Feb 2002 | A1 |
20020040035 | Myers et al. | Apr 2002 | A1 |
20020077675 | Greenstein | Jun 2002 | A1 |
20020086871 | O'Neill et al. | Jul 2002 | A1 |
20020095139 | Keogh et al. | Jul 2002 | A1 |
20020099417 | Naritoku et al. | Jul 2002 | A1 |
20020138075 | Edwards et al. | Sep 2002 | A1 |
20020138109 | Keogh et al. | Sep 2002 | A1 |
20020193859 | Schulman et al. | Dec 2002 | A1 |
20020198570 | Puskas | Dec 2002 | A1 |
20030018367 | DiLorenzo | Jan 2003 | A1 |
20030045909 | Gross et al. | Mar 2003 | A1 |
20030088301 | King | May 2003 | A1 |
20030191404 | Klein | Oct 2003 | A1 |
20030194752 | Anderson et al. | Oct 2003 | A1 |
20030195578 | Perron et al. | Oct 2003 | A1 |
20030212440 | Boveja | Nov 2003 | A1 |
20030229380 | Adams et al. | Dec 2003 | A1 |
20030236557 | Whitehurst et al. | Dec 2003 | A1 |
20030236558 | Whitehurst et al. | Dec 2003 | A1 |
20040002546 | Altschuler | Jan 2004 | A1 |
20040015202 | Chandler et al. | Jan 2004 | A1 |
20040015205 | Whitehurst et al. | Jan 2004 | A1 |
20040024422 | Hill et al. | Feb 2004 | A1 |
20040024428 | Barrett et al. | Feb 2004 | A1 |
20040024439 | Riso | Feb 2004 | A1 |
20040030362 | Hill et al. | Feb 2004 | A1 |
20040039427 | Barrett et al. | Feb 2004 | A1 |
20040048795 | Ivanova et al. | Mar 2004 | A1 |
20040049121 | Yaron | Mar 2004 | A1 |
20040049240 | Gerber et al. | Mar 2004 | A1 |
20040059383 | Puskas | Mar 2004 | A1 |
20040111139 | McCreery et al. | Jun 2004 | A1 |
20040138517 | Osorio et al. | Jul 2004 | A1 |
20040138518 | Rise et al. | Jul 2004 | A1 |
20040138536 | Frei et al. | Jul 2004 | A1 |
20040146949 | Tan et al. | Jul 2004 | A1 |
20040153127 | Gordon et al. | Aug 2004 | A1 |
20040158119 | Osorio et al. | Aug 2004 | A1 |
20040162584 | Hill et al. | Aug 2004 | A1 |
20040172074 | Yoshihito | Sep 2004 | A1 |
20040172085 | Knudson et al. | Sep 2004 | A1 |
20040172086 | Knudson et al. | Sep 2004 | A1 |
20040172088 | Knudson et al. | Sep 2004 | A1 |
20040172094 | Cohen et al. | Sep 2004 | A1 |
20040176812 | Knudson et al. | Sep 2004 | A1 |
20040178706 | D'Orso | Sep 2004 | A1 |
20040193231 | David et al. | Sep 2004 | A1 |
20040199209 | Hill et al. | Oct 2004 | A1 |
20040199210 | Shelchuk | Oct 2004 | A1 |
20040204355 | Tracey et al. | Oct 2004 | A1 |
20040215272 | Haubrich et al. | Oct 2004 | A1 |
20040215287 | Swoyer et al. | Oct 2004 | A1 |
20040236381 | Dinsmoor et al. | Nov 2004 | A1 |
20040236382 | Dinsmoor et al. | Nov 2004 | A1 |
20040240691 | Grafenberg | Dec 2004 | A1 |
20040243182 | Cohen et al. | Dec 2004 | A1 |
20040254612 | Ezra et al. | Dec 2004 | A1 |
20040267152 | Pineda | Dec 2004 | A1 |
20050021092 | Yun et al. | Jan 2005 | A1 |
20050021101 | Chen et al. | Jan 2005 | A1 |
20050027328 | Greenstein | Feb 2005 | A1 |
20050043774 | Devlin et al. | Feb 2005 | A1 |
20050049655 | Boveja et al. | Mar 2005 | A1 |
20050065553 | Ben Ezra et al. | Mar 2005 | A1 |
20050065573 | Rezai | Mar 2005 | A1 |
20050065575 | Dobak | Mar 2005 | A1 |
20050070970 | Knudson et al. | Mar 2005 | A1 |
20050070974 | Knudson et al. | Mar 2005 | A1 |
20050075701 | Shafer | Apr 2005 | A1 |
20050075702 | Shafer | Apr 2005 | A1 |
20050095246 | Shafer | May 2005 | A1 |
20050096707 | Hill et al. | May 2005 | A1 |
20050103351 | Stomberg et al. | May 2005 | A1 |
20050131467 | Boveja | Jun 2005 | A1 |
20050131486 | Boveja et al. | Jun 2005 | A1 |
20050131487 | Boveja | Jun 2005 | A1 |
20050131493 | Boveja et al. | Jun 2005 | A1 |
20050137644 | Boveja et al. | Jun 2005 | A1 |
20050137645 | Voipio et al. | Jun 2005 | A1 |
20050143781 | Carbunaru et al. | Jun 2005 | A1 |
20050143787 | Boveja et al. | Jun 2005 | A1 |
20050149126 | Libbus | Jul 2005 | A1 |
20050149129 | Libbus et al. | Jul 2005 | A1 |
20050149131 | Libbus et al. | Jul 2005 | A1 |
20050153885 | Yun et al. | Jul 2005 | A1 |
20050154425 | Boveja et al. | Jul 2005 | A1 |
20050154426 | Boveja et al. | Jul 2005 | A1 |
20050165458 | Boveja et al. | Jul 2005 | A1 |
20050177200 | George et al. | Aug 2005 | A1 |
20050182288 | Zabara | Aug 2005 | A1 |
20050182467 | Hunter et al. | Aug 2005 | A1 |
20050187584 | Denker et al. | Aug 2005 | A1 |
20050187586 | David et al. | Aug 2005 | A1 |
20050187590 | Boveja et al. | Aug 2005 | A1 |
20050191661 | Gatanaga et al. | Sep 2005 | A1 |
20050192644 | Boveja et al. | Sep 2005 | A1 |
20050197600 | Schuler et al. | Sep 2005 | A1 |
20050197675 | David et al. | Sep 2005 | A1 |
20050197678 | Boveja et al. | Sep 2005 | A1 |
20050203501 | Aldrich et al. | Sep 2005 | A1 |
20050209654 | Boveja et al. | Sep 2005 | A1 |
20050216064 | Heruth et al. | Sep 2005 | A1 |
20050216070 | Boveja et al. | Sep 2005 | A1 |
20050216071 | Devlin et al. | Sep 2005 | A1 |
20050240229 | Whitehurst et al. | Oct 2005 | A1 |
20050240231 | Aldrich et al. | Oct 2005 | A1 |
20050240241 | Yun et al. | Oct 2005 | A1 |
20050240242 | DiLorenzo | Oct 2005 | A1 |
20050251220 | Barrett et al. | Nov 2005 | A1 |
20050251222 | Barrett et al. | Nov 2005 | A1 |
20050267542 | David et al. | Dec 2005 | A1 |
20050267547 | Knudson et al. | Dec 2005 | A1 |
20050277912 | John | Dec 2005 | A1 |
20050283198 | Haubrich et al. | Dec 2005 | A1 |
20060009815 | Boveja et al. | Jan 2006 | A1 |
20060015151 | Aldrich | Jan 2006 | A1 |
20060025828 | Armstrong et al. | Feb 2006 | A1 |
20060036293 | Whitehurst et al. | Feb 2006 | A1 |
20060052657 | Zabara | Mar 2006 | A9 |
20060052831 | Fukui | Mar 2006 | A1 |
20060052836 | Kim et al. | Mar 2006 | A1 |
20060058851 | Cigaina | Mar 2006 | A1 |
20060064137 | Stone | Mar 2006 | A1 |
20060064139 | Chung et al. | Mar 2006 | A1 |
20060074450 | Boveja et al. | Apr 2006 | A1 |
20060074473 | Gertner | Apr 2006 | A1 |
20060079936 | Boveja et al. | Apr 2006 | A1 |
20060085046 | Rezai et al. | Apr 2006 | A1 |
20060095081 | Zhou et al. | May 2006 | A1 |
20060095090 | De Ridder | May 2006 | A1 |
20060100668 | Ben-David et al. | May 2006 | A1 |
20060106755 | Stuhec | May 2006 | A1 |
20060111644 | Guttag et al. | May 2006 | A1 |
20060111754 | Rezai et al. | May 2006 | A1 |
20060111755 | Stone et al. | May 2006 | A1 |
20060116739 | Betser et al. | Jun 2006 | A1 |
20060122675 | Libbus et al. | Jun 2006 | A1 |
20060129200 | Kurokawa | Jun 2006 | A1 |
20060129202 | Armstrong | Jun 2006 | A1 |
20060135998 | Libbus et al. | Jun 2006 | A1 |
20060142802 | Armstrong | Jun 2006 | A1 |
20060142822 | Tulgar | Jun 2006 | A1 |
20060149337 | John | Jul 2006 | A1 |
20060155495 | Osorio et al. | Jul 2006 | A1 |
20060161216 | John et al. | Jul 2006 | A1 |
20060161217 | Jaax et al. | Jul 2006 | A1 |
20060167497 | Armstrong et al. | Jul 2006 | A1 |
20060167498 | DiLorenzo | Jul 2006 | A1 |
20060167501 | Ben-David et al. | Jul 2006 | A1 |
20060173493 | Armstrong et al. | Aug 2006 | A1 |
20060173508 | Stone et al. | Aug 2006 | A1 |
20060178691 | Binmoeller | Aug 2006 | A1 |
20060178703 | Huston et al. | Aug 2006 | A1 |
20060178706 | Lisogurski et al. | Aug 2006 | A1 |
20060190044 | Libbus et al. | Aug 2006 | A1 |
20060200208 | Terry, Jr. et al. | Sep 2006 | A1 |
20060200219 | Thrope et al. | Sep 2006 | A1 |
20060206155 | Ben-David et al. | Sep 2006 | A1 |
20060206158 | Wu et al. | Sep 2006 | A1 |
20060229677 | Moffitt et al. | Oct 2006 | A1 |
20060229681 | Fischell | Oct 2006 | A1 |
20060241699 | Libbus et al. | Oct 2006 | A1 |
20060247719 | Maschino et al. | Nov 2006 | A1 |
20060247721 | Maschino et al. | Nov 2006 | A1 |
20060247722 | Maschino et al. | Nov 2006 | A1 |
20060259077 | Pardo et al. | Nov 2006 | A1 |
20060259084 | Zhang et al. | Nov 2006 | A1 |
20060259085 | Zhang et al. | Nov 2006 | A1 |
20060259107 | Caparso et al. | Nov 2006 | A1 |
20060271115 | Ben-Ezra et al. | Nov 2006 | A1 |
20060282121 | Payne et al. | Dec 2006 | A1 |
20060282131 | Caparso et al. | Dec 2006 | A1 |
20060282145 | Caparso et al. | Dec 2006 | A1 |
20060287678 | Shafer | Dec 2006 | A1 |
20060287679 | Stone | Dec 2006 | A1 |
20060292099 | Milburn et al. | Dec 2006 | A1 |
20060293720 | DiLorenzo | Dec 2006 | A1 |
20060293721 | Tarver et al. | Dec 2006 | A1 |
20060293723 | Whitehurst et al. | Dec 2006 | A1 |
20070016262 | Gross et al. | Jan 2007 | A1 |
20070016263 | Armstrong et al. | Jan 2007 | A1 |
20070021785 | Inman et al. | Jan 2007 | A1 |
20070021786 | Parnis et al. | Jan 2007 | A1 |
20070021814 | Inman et al. | Jan 2007 | A1 |
20070025608 | Armstrong | Feb 2007 | A1 |
20070027482 | Parnis et al. | Feb 2007 | A1 |
20070027483 | Maschino et al. | Feb 2007 | A1 |
20070027484 | Guzman et al. | Feb 2007 | A1 |
20070027486 | Armstrong | Feb 2007 | A1 |
20070027492 | Maschino et al. | Feb 2007 | A1 |
20070027496 | Parnis et al. | Feb 2007 | A1 |
20070027497 | Parnis | Feb 2007 | A1 |
20070027498 | Maschino et al. | Feb 2007 | A1 |
20070027499 | Maschino et al. | Feb 2007 | A1 |
20070027500 | Maschino et al. | Feb 2007 | A1 |
20070027504 | Barrett et al. | Feb 2007 | A1 |
20070055324 | Thompson et al. | Mar 2007 | A1 |
20070067004 | Boveja et al. | Mar 2007 | A1 |
20070083242 | Mazgalev et al. | Apr 2007 | A1 |
20070093434 | Rossetti et al. | Apr 2007 | A1 |
20070093870 | Maschino | Apr 2007 | A1 |
20070093875 | Chavan et al. | Apr 2007 | A1 |
20070100263 | Merfeld | May 2007 | A1 |
20070100377 | Armstrong et al. | May 2007 | A1 |
20070100378 | Maschino | May 2007 | A1 |
20070100380 | Fukui | May 2007 | A1 |
20070100392 | Maschino et al. | May 2007 | A1 |
20070106339 | Errico et al. | May 2007 | A1 |
20070112404 | Mann et al. | May 2007 | A1 |
20070118177 | Libbus et al. | May 2007 | A1 |
20070118178 | Fukui | May 2007 | A1 |
20070129767 | Wahlstrand | Jun 2007 | A1 |
20070129780 | Whitehurst et al. | Jun 2007 | A1 |
20070135846 | Knudson et al. | Jun 2007 | A1 |
20070135856 | Knudson et al. | Jun 2007 | A1 |
20070135857 | Knudson et al. | Jun 2007 | A1 |
20070135858 | Knudson et al. | Jun 2007 | A1 |
20070142870 | Knudson et al. | Jun 2007 | A1 |
20070142871 | Libbus et al. | Jun 2007 | A1 |
20070142874 | John | Jun 2007 | A1 |
20070150006 | Libbus et al. | Jun 2007 | A1 |
20070150011 | Meyer et al. | Jun 2007 | A1 |
20070150021 | Chen et al. | Jun 2007 | A1 |
20070150027 | Rogers | Jun 2007 | A1 |
20070156180 | Jaax et al. | Jul 2007 | A1 |
20070198063 | Hunter et al. | Aug 2007 | A1 |
20070239243 | Moffitt et al. | Oct 2007 | A1 |
20070244522 | Overstreet | Oct 2007 | A1 |
20070250145 | Kraus et al. | Oct 2007 | A1 |
20070255320 | Inman et al. | Nov 2007 | A1 |
20070255333 | Giftakis | Nov 2007 | A1 |
20070255339 | Torgerson | Nov 2007 | A1 |
20080021517 | Dietrich | Jan 2008 | A1 |
20080021520 | Dietrich | Jan 2008 | A1 |
20080046055 | Durand et al. | Feb 2008 | A1 |
20080051852 | Dietrich et al. | Feb 2008 | A1 |
20080058871 | Libbus et al. | Mar 2008 | A1 |
20080103407 | Bolea et al. | May 2008 | A1 |
20080140138 | Ivanova et al. | Jun 2008 | A1 |
20080183226 | Buras et al. | Jul 2008 | A1 |
20080183246 | Patel et al. | Jul 2008 | A1 |
20080195171 | Sharma | Aug 2008 | A1 |
20080208266 | Lesser et al. | Aug 2008 | A1 |
20080213331 | Gelfand et al. | Sep 2008 | A1 |
20080234790 | Bayer et al. | Sep 2008 | A1 |
20080281365 | Tweden et al. | Nov 2008 | A1 |
20080281372 | Libbus et al. | Nov 2008 | A1 |
20090012590 | Inman et al. | Jan 2009 | A1 |
20090048194 | Aerssens et al. | Feb 2009 | A1 |
20090082832 | Carbunaru et al. | Mar 2009 | A1 |
20090088821 | Abrahamson | Apr 2009 | A1 |
20090105782 | Mickle et al. | Apr 2009 | A1 |
20090112291 | Wahlstrand et al. | Apr 2009 | A1 |
20090123521 | Weber et al. | May 2009 | A1 |
20090125079 | Armstrong et al. | May 2009 | A1 |
20090143831 | Huston et al. | Jun 2009 | A1 |
20090171405 | Craig | Jul 2009 | A1 |
20090177112 | Gharib et al. | Jul 2009 | A1 |
20090187231 | Errico et al. | Jul 2009 | A1 |
20090248097 | Tracey et al. | Oct 2009 | A1 |
20090254143 | Tweden et al. | Oct 2009 | A1 |
20090275997 | Faltys et al. | Nov 2009 | A1 |
20090276019 | Perez et al. | Nov 2009 | A1 |
20090281593 | Errico et al. | Nov 2009 | A9 |
20090312817 | Hogle et al. | Dec 2009 | A1 |
20100003656 | Kilgard et al. | Jan 2010 | A1 |
20100010556 | Zhao et al. | Jan 2010 | A1 |
20100010571 | Skelton et al. | Jan 2010 | A1 |
20100010581 | Goetz et al. | Jan 2010 | A1 |
20100010603 | Ben-David et al. | Jan 2010 | A1 |
20100016746 | Hampton et al. | Jan 2010 | A1 |
20100042186 | Ben-David et al. | Feb 2010 | A1 |
20100063563 | Craig | Mar 2010 | A1 |
20100074934 | Hunter | Mar 2010 | A1 |
20100191304 | Scott | Jul 2010 | A1 |
20100215632 | Boss et al. | Aug 2010 | A1 |
20100241183 | DiLorenzo | Sep 2010 | A1 |
20100249859 | DiLorenzo | Sep 2010 | A1 |
20100280562 | Pi et al. | Nov 2010 | A1 |
20100280569 | Bobillier et al. | Nov 2010 | A1 |
20110004266 | Sharma | Jan 2011 | A1 |
20110054569 | Zitnik et al. | Mar 2011 | A1 |
20110066208 | Pasricha et al. | Mar 2011 | A1 |
20110082515 | Libbus et al. | Apr 2011 | A1 |
20110092882 | Firlik et al. | Apr 2011 | A1 |
20110144717 | Burton et al. | Jun 2011 | A1 |
20110190849 | Faltys | Aug 2011 | A1 |
20110224749 | Ben-David et al. | Sep 2011 | A1 |
20110307027 | Sharma et al. | Dec 2011 | A1 |
20120053657 | Parker et al. | Mar 2012 | A1 |
20120065706 | Vallapureddy et al. | Mar 2012 | A1 |
20120179219 | Kisker | Jul 2012 | A1 |
20120185009 | Kornet et al. | Jul 2012 | A1 |
20120185020 | Simon et al. | Jul 2012 | A1 |
20130013016 | Diebold | Jan 2013 | A1 |
20130066392 | Simon et al. | Mar 2013 | A1 |
20130066395 | Simon et al. | Mar 2013 | A1 |
20130079834 | Levine | Mar 2013 | A1 |
20130245718 | Birkholz et al. | Sep 2013 | A1 |
20130317580 | Simon et al. | Nov 2013 | A1 |
20140046407 | Ben-Ezra et al. | Feb 2014 | A1 |
20140288551 | Bharmi et al. | Sep 2014 | A1 |
20140330335 | Errico et al. | Nov 2014 | A1 |
20150018728 | Gross et al. | Jan 2015 | A1 |
20150100100 | Tracey et al. | Apr 2015 | A1 |
20150119956 | Libbus et al. | Apr 2015 | A1 |
20150241447 | Zitnik et al. | Aug 2015 | A1 |
20160038745 | Faltys et al. | Feb 2016 | A1 |
20160051813 | Faltys et al. | Feb 2016 | A1 |
20160067497 | Levine et al. | Mar 2016 | A1 |
20160096016 | Tracey et al. | Apr 2016 | A1 |
20160096017 | Levine et al. | Apr 2016 | A1 |
20160114165 | Levine et al. | Apr 2016 | A1 |
20160250097 | Tracey et al. | Sep 2016 | A9 |
20160331952 | Faltys et al. | Nov 2016 | A1 |
20160367808 | Simon et al. | Dec 2016 | A9 |
20170266448 | Tracey et al. | Sep 2017 | A1 |
20170304613 | Faltys et al. | Oct 2017 | A1 |
20180021580 | Tracey et al. | Jan 2018 | A1 |
20190022389 | Leonhardt | Jan 2019 | A1 |
20190192847 | Faltys et al. | Jun 2019 | A1 |
Number | Date | Country |
---|---|---|
201230913 | May 2009 | CN |
101528303 | Sep 2009 | CN |
101578067 | Nov 2009 | CN |
101868280 | Oct 2010 | CN |
2628045 | Jan 1977 | DE |
3736664 | May 1989 | DE |
20316509 | Apr 2004 | DE |
0438510 | Aug 1996 | EP |
0726791 | Jun 2000 | EP |
1001827 | Jan 2004 | EP |
2213330 | Aug 2010 | EP |
2073896 | Oct 2011 | EP |
04133 | Feb 1910 | GB |
20050039445 | Apr 2005 | KR |
WO9301862 | Feb 1993 | WO |
WO9730998 | Aug 1997 | WO |
WO9820868 | May 1998 | WO |
WO0027381 | May 2000 | WO |
WO0047104 | Aug 2000 | WO |
WO0100273 | Jan 2001 | WO |
WO0108617 | Feb 2001 | WO |
WO0189526 | Nov 2001 | WO |
WO0244176 | Jun 2002 | WO |
WO02057275 | Jul 2002 | WO |
WO03072135 | Sep 2003 | WO |
WO2004000413 | Dec 2003 | WO |
WO2004064918 | Aug 2004 | WO |
WO2006073484 | Jul 2006 | WO |
WO2006076681 | Jul 2006 | WO |
WO2007133718 | Nov 2007 | WO |
WO2010005482 | Jan 2010 | WO |
WO2010067360 | Jun 2010 | WO |
WO2010118035 | Oct 2010 | WO |
Entry |
---|
US 6,184,239 B1, 02/2001, Puskas (withdrawn) |
Levine et al.; U.S. Appl. No. 16/103,873 entitled “Vagus nerve stimulation pre-screening test,” filed Aug. 14, 2018. |
Levine et al.; U.S. Appl. No. 16/157,222 entitled “Vagus nerve stimulation to treat neurodegenerative disorders,” filed Oct. 11, 2018. |
Cavaillon et al.; The pro-inflammatory cytokine casade; Immune Response in the Critically Ill; Springer-Verlag Berlin Hiedelberg; pp. 37-66; Jan. 21, 2002. |
Faltys et al.; U.S. Appl. No. 15/543,391 entitled “Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator,” filed Jul. 13, 2017. |
Tracey et al.; U.S. Appl. No. 15/716,408 entitled “Treatment of bleeding by non-invasive stimulation,” filed Sep. 26, 2017. |
Abraham, Coagulation abnormalities in acute lung injury and sepsis, Am. J. Respir. Cell Mol. Biol., vol. 22(4), pp. 401-404, Apr. 2000. |
Aekerlund et al., Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-Alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats, Clinical & Experimental Immunology, vol. 115, No. 1, pp. 32-41, Jan. 1, 1999. |
Anderson et al.; Reflex principles of immunological homeostasis; Annu. Rev. Immunol.; 30; pp. 313-335; Apr. 2012. |
Antonica, A., et al., Vagal control of lymphocyte release from rat thymus, J. Auton. Nerv. Syst., vol. 48(3), pp. 187-197, Aug. 1994. |
Asakura et al., Non-surgical therapy for ulcerative colitis, Nippon Geka Gakkai Zasshi, vol. 98, No. 4, pp. 431-437, Apr. 1997 (abstract only). |
Beliavskaia et al., “On the effects of prolonged stimulation of the peripheral segment of the vagus nerve . . . ,” Fiziologicheskii Zhurnal SSSR Imeni I.M. Sechenova., vol. 52(11); p. 1315-1321, Nov. 1966. |
Ben-Noun et al.; Neck circumference as a simple screening measure for identifying overweight and obese patients; Obesity Research; vol. 9; No. 8; pp. 470-477; Aug. 8, 2001. |
Benoist, et al., “Mast cells in autoimmune disease” Nature., vol. 420(19): pp. 875-878, Dec. 2002. |
Benthem et al.; Parasympathetic inhibition of sympathetic neural activity to the pancreas; Am.J.Physiol Endocrinol.Metab; 280(2); pp. E378-E381; Feb. 2001. |
Bernik et al., Vagus nerve stimulation attenuates cardiac TNF production in endotoxic shock, (supplemental to SHOCK, vol. 15, 2001, Injury, inflammation and sepsis: laboratory and clinical approaches, SHOCK, Abstracts, 24th Annual Conference on Shock, Marco Island, FL, Jun. 9-12, 2001), Abstract No. 81. |
Bernik et al., Vagus nerve stimulation attenuates endotoxic shock and cardiac TNF production, 87th Clinical Congress of the American College of Surgeons, New Orleans, LA, Oct. 9, 2001. |
Bernik et al., Vagus nerve stimulation attenuates LPS-induced cardiac TNF production and myocardial depression in shock, New York Surgical Society, New York, NY, Apr. 11, 2001. |
Bernik, et al., Pharmacological stimulation of the cholinergic anti-inflammatory pathway, The Journal of Experimental Medicine, vol. 195, No. 6, pp. 781-788, Mar. 18, 2002. |
Besedovsky, H., et al., lmmunoregulatory feedback between interleukin-1 and glucocorticoid hormones, Science, vol. 233, No. 4764, pp. 652-654, Aug. 1986. |
Bhattacharya, S.K. et al., Central muscarinic receptor subtypes and carrageenin-induced paw oedema in rats, Res. Esp. Med. vol. 191(1), pp. 65-76, Dec. 1991. |
Bianchi et al., Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone, Journal of Experimental Medicine, vol. 183, pp. 927-936, Mar. 1996. |
Biggio et al.; Chronic vagus nerve stimulation induces neuronal plasticity in the rat hippocampus; Int. J. Neurpsychopharmacol.; vol. 12; No. 9; pp. 1209-1221; Oct. 2009. |
Blackwell, T. S. et al., Sepsis and cytokines: current status, Br. J. Anaesth., vol. 77(1), pp. 110-117, Jul. 1996. |
Blum, A. et al., Role of cytokines in heart failure, Am. Heart J., vol. 135(2), pp. 181-186, Feb. 1998. |
Boldyreff, Gastric and intestinal mucus, its properties and physiological importance, Acta Medica Scandinavica (journal), vol. 89, Issue 1-2, pp. 1-14, Jan./Dec. 1936. |
Borovikova et al., Acetylcholine inhibition of immune response to bacterial endotoxin in human macrophages, Abstracts, Society for Neuroscience, 29th Annual Meeting, Miami Beach, FL, (Abs. No. 624.6); Oct. 23-28, 1999. |
Borovikova et al., Efferent vagus nerve activity attenuates cytokine-mediated inflammation, Society for Neuroscience Abstracts, vol. 26, No. 102, Nov. 4-9, 2000 (abstract only). |
Borovikova et al., Intracerebroventricular CNI-1493 prevents LPS-induced hypotension and peak serum TNF at a four-log lower dose than systemic treatment, 21st Annual Conference on Shock, San Antonio, TX, Jun. 14-17, 1998, Abstract No. 86. |
Borovikova et al., Role of the efferent vagus nerve signaling in the regulation of the innate immune response to LPS, (supplemental to SHOCK, vol. 13, 2000, Molecular, cellular, and systemic pathobiological aspects and therapeutic approaches, abstracts, 5th World Congress on Trauma, Shock inflammation and sepsis-pathophysiology, immune consequences and therapy, Feb. 29, 2000-Mar. 4, 2000, Munich, DE), Abstract No. 166. |
Borovikova et al., Role of the vagus nerve in the anti-inflammatory effects of CNI-1493, the FASEB journal, vol. 14, No. 4, 2000 (Experimental Biology 2000, San Diego, CA, Apr. 15-18, 2000, Abstract No. 97.9). |
Borovikova et al., Vagotomy blocks the protective effects of I.C.V. CNI-1493 against LPS-induced shock, (Supplemental to SHOCK, vol. 11, 1999, Molecular, cellular, and systemic pathobioloigal aspects and therapeutic approaches, abstacts and program, Fourth International Shock Congress and 22nd Annual Conference on Shock, Philadelphia, PA, Jun. 12-16, 1999), Abstract No. 277. |
Borovikova, L. V., et al., Role of vagus nerve signaling in CNI-1493—mediated suppression of acute inflammation, Autonomic Neuroscience, vol. 85, No. 1-3, pp. 141-147, Dec. 20, 2000. |
Borovikova, L. V., et al., Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin, Nature, vol. 405, No. 6785: pp. 458-462, May 25, 2000. |
Bruchfeld et al.; Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis; J. Int. Med.; 268(1); pp. 94-101; Jul. 2010. |
Bulloch et al.; Characterization of choline O-acetyltransferase (ChAT) in the BALB/C mouse spleen; Int.J.Neurosci.; 76(1-2); pp. 141-149; May 1994. |
Bumgardner, G. L. et al., Transplantation and cytokines, Seminars in Liver Disease, vol. 19, No. 2, Thieme Medical Publishers; pp. 189-204, © 1999. |
Burke et al., Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase, J. Mol. Biol., vol. 264(4); pp. 650-666, Dec. 1996. |
Bushby et al; Centiles for adult head circumference; Archives of Disease in Childhood; vol. 67(10); pp. 1286-1287; Oct. 1992. |
Cano et al.; Characterization of the central nervous system innervation of the rat spleen using viral transneuronal tracing; J.Comp Neurol.; 439(1); pp. 1-18; Oct. 2001. |
Carteron, N. L., Cytokines in rheumatoid arthritis: trials and tribulations, Mol. Med. Today, vol. 6(8), pp. 315-323, Aug. 2000. |
Cheyuo et al.; The parasympathetic nervous system in the quest for stroke therapeutics; J. Cereb. Blood Flow Metab.; 31(5); pp. 1187-1195; May 2011. |
Cicala et al., “Linkage between inflammation and coagulation: An update on the molecular basis of the crosstalk,” Life Sciences, vol. 62(20); pp. 1817-1824, Apr. 1998. |
Clark et al.; Enhanced recognition memory following vagus nerve stimulation in human subjects; Nat. Neurosci.; 2(1); pp. 94-98; Jan. 1999. |
Cohen, “The immunopathogenesis of sepsis,” Nature., vol. 420(6917): pp. 885-891, Dec. 2002. |
Corcoran, et al., The effects of vagus nerve stimulation on pro- and anti-inflammatory cytokines in humans: a preliminary report, NeuroImmunoModulation, vol. 12(5), pp. 307-309, Sep. 2005. |
Dake; Chronic cerebrospinal venous insufficiency and multiple sclerosis: Hostory and background; Techniques Vasc. Intervent. Radiol.; 15(2); pp. 94-100; Jun. 2012. |
Das, Critical advances in spticemia and septic shock, Critical Care, vol. 4, pp. 290-296, 7 Sep. 2000. |
Del Signore et al; Nicotinic acetylcholine receptor subtypes in the rat sympathetic ganglion: pharmacological characterization, subcellular distribution and effect of pre- and postganglionic nerve crush; J.Neuropathol.Exp.Neurol.; 63(2); pp. 138-150; Feb. 2004. |
Diamond et al.; Mapping the immunological homunculus; Proc. Natl. Acad. Sci. USA; 108(9); pp. 3461-3462; Mar. 1, 2011. |
Dibbs, Z., et al., Cytokines in heart failure: pathogenetic mechanisms and potential treatment, Proc. Assoc. Am. Physicians, vol. 111, No. 5, pp. 423-428, Sep.-Oct. 1999. |
Dinarello, C. A., The interleukin-1 family: 10 years of discovery, FASEB J., vol. 8, No. 15, pp. 1314-1325, Dec. 1994. |
Dorr et al.; Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission; J. Pharmacol. Exp. Ther.; 318(2); pp. 890-898; Aug. 2006. |
Doshi et al., Evolving role of tissue factor and its pathway inhibitor, Crit. Care Med., vol. 30, suppl. 5, pp. S241-S250, May 2002. |
Elenkov et al.; Stress, corticotropin-releasing hormone, glucocorticoids, and the immune / inflammatory response: acute and chronic effects; Ann. N.Y. Acad. Sci.; 876; pp. 1-13; Jun. 22, 1999. |
Ellington et al., In vitro selection of RNA molecules that bind specific ligands, Nature, vol. 346, pp. 818-822, Aug. 30, 1990. |
Ellrich et al.; Transcutaneous vagus nerve stimulation; Eur. Neurological Rev.; 6(4); pp. 254-256; Winter 2011. |
Engineer et al.; Directing neural plasticity to understand and treat tinnitus; Hear. Res.; 295; pp. 58-66; Jan. 2013. |
Engineer et al.; Reversing pathological neural activity using targeted plasticity; Nature; 470(7332); pp. 101-104; Feb. 3, 2011 (Author Manuscript). |
Esmon, The protein C pathway, Crit. Care Med., vol. 28, suppl. 9, pp. S44-S48, Sep. 2000. |
Fields; New culprits in chronic pain; Scientific American; pp. 50-57; Nov. 2009. |
Fleshner, M., et al., Thermogenic and corticosterone responses to intravenous cytokines (IL-1? and TNF-?) are attenuated by subdiaphragmatic vagotomy, J. Neuroimmunol., vol. 86(2), pp. 134-141, Jun. 1998. |
Fox, D. A., Cytokine blockade as a new strategy to treat rheumatoid arthritis, Arch. Intern. Med., vol. 160, pp. 437-444, Feb. 28, 2000. |
Fox, et al., Use of muscarinic agonists in the treatment of Sjorgren' syndrome, Clin. Immunol., vol. 101, No. 3; pp. 249-263, Dec. 2001. |
Fujii et al.; Simvastatin regulates non-neuronal cholinergic activity in T lymphocytes via CD11a-mediated pathways; J. Neuroimmunol.; 179(1-2); pp. 101-107; Oct. 2006. |
Gao et al.; Investigation of specificity of auricular acupuncture points in regulation of autonomic function in anesthetized rats; Autonomic Neurosc.; 138(1-2); pp. 50-56; Feb. 29, 2008. |
Gattorno, M., et al., Tumor necrosis factor induced adhesion molecule serum concentrations in henoch-schoenlein purpura and pediatric systemic lupus erythematosus, J. Rheumatol., vol. 27, No. 9, pp. 2251-2255, Sep. 2000. |
Gaykema, R. P., et al., Subdiaphragmatic vagotomy suppresses endotoxin-induced activation of hypothalamic corticotropin-releasing hormone neurons and ACTH secretion, Endocrinology, vol. 136, No. 10, pp. 4717-4720, Oct. 1995. |
Ghelardini et al., S-(−)-ET 126: A potent and selective M1 antagonist in vitro and in vivo, Life Sciences, vol. 58, No. 12, pp. 991-1000, Feb. 1996. |
Ghia, et al., The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model, Gastroenterology, vol. 131, No. 4, pp. 1122-1130, Oct. 2006. |
Giebelen, et al., Stimulation of ?7 cholinergic receptors inhibits lipopolysaccharide-induced neutrophil recruitment by a tumor necrosis factor ?-independent mechanism, SHOCK, vol. 27, No. 4, pp. 443-447, Apr. 2007. |
Goyal et al., Nature of the vagal inhibitory innervation to the lower esophageal sphincter, Journal of Clinical Investigation, vol. 55, pp. 1119-1126, May 1975. |
Gracie, J. A., et al., A proinflammatory role for IL-18 in rheumatoid arthritis, J. Clin. Invest., vol. 104, No. 10, pp. 1393-1401, Nov. 1999. |
Granert et al., Suppression of macrophage activation with CNI-1493 increases survival in infant rats with systemic haemophilus influenzae infection, Infection and Immunity, vol. 68, No. 9, pp. 5329-5334, Sep. 2000. |
Green et al., Feedback technique for deep relaxation, Psycophysiology, vol. 6, No. 3, pp. 371-377, Nov. 1969. |
Gregory et al., Neutrophil-kupffer-cell interaction in host defenses to systemic infections, Immunology Today, vol. 19, No. 11, pp. 507-510, Nov. 1998. |
Groves et al.; Recordings from the rat locus coeruleus during acute vagal nerve stimulation in the anaesthetised rat; Neuroscience Letters; 379(3); pp. 174-179; May 13, 2005. |
Guarente, Leonard, Ph. D.; Sirtuins, Aging, and Medicine; N Engl J Med ; vol. 364:pp. 2235-2244; Jun. 2011. |
Guslandi, M., Nicotine treatment for ulcerative colitis, Br. J. Clin. Pharmacol., vol. 48(4), pp. 481-484, Oct. 1999. |
Hansson, E.; Could chronic pain and spread of pain sensation be induced and maintained by glial activation?. Acta Physiologica, vol. 187, Issue 1-2; pp. 321R327, May/Jun. 2006. |
Harrison's Principles of Internal Medicine, 13th Ed., pp. 511-515 and 1433-1435, Mar. 1994. |
Hatton et al.; Vagal nerve stimulation: overview and implications for anesthesiologists; Int'l Anesthesia Research Society; vol. 103; No. 5; pp. 1241-1249; Nov. 2006. |
Hirano, T., Cytokine suppresive agent improves survival rate in rats with acute pancreatitis of closed duodenal loop, J. Surg. Res., vol. 81, No. 2, pp. 224-229, Feb. 1999. |
Hirao et al., The limits of specificity: an experimental analysis with RNA aptamers to MS2 coat protein variants, Mol. Divers., vol. 4, No. 2, pp. 75-89, 1999 (Accepted Jan. 13, 1999). |
Hoffer et al.; Implantable electrical and mechanical interfaces with nerve and muscle; Annals of Biomedical Engineering; vol. 8; pp. 351-360; Jul. 1980. |
Holladay et al., Neuronal nicotinic acetylcholine receptors as targets for drug discovery, Journal of Medicinal Chemistry, 40(26), pp. 4169-4194, Dec. 1997. |
Hommes, D. W. et al., Anti- and Pro-inflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease, Current Opinion in Clinical Nutrition and Metabolic Care, vol. 3(3), pp. 191-195, May 2000. |
Hsu, et al., Analysis of efficiency of magnetic stimulation, IEEE Trans. Biomed. Eng., vol. 50(11), pp. 1276-1285, Nov. 2003. |
Hsu, H. Y., et al., Cytokine release of peripheral blood monoculear cells in children with chronic hepatitis B virus infection, J. Pediatr. Gastroenterol., vol. 29, No. 5, pp. 540-545, Nov. 1999. |
Hu, et al., The effect of norepinephrine on endotoxin-mediated macrophage activation, J. NeuroImmunol., vol. 31(1), pp. 35-42, Jan. 1991. |
Huston et al.; Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis; J. Exp. Med. 2006; vol. 203, No. 7; pp. 1623-1628; Jun. 19, 2006. |
Huston et al.; Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis; Crit. Care Med.; 35(12); pp. 2762-2768; Dec. 2007. |
Hutchinson et al.; Proinflammatory cytokines oppose opioid induced acute and chronic analgesia; Brain Behav Immun.; vol. 22; No. 8; pp. 1178-1189; Nov. 2008. |
Ilton et al., “Differential expression of neutrophil adhesion molecules during coronary artery surgery with cardiopulmonary bypass” Journal of Thoracic and Cardiovascular Surgery, Mosby—Year Book, inc., St. Louis, MO, US, pp. 930-937, Nov. 1, 1999. |
Jaeger et al., The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor, The EMBO Journal, 17(15), pp. 4535-4542, Aug. 1998. |
Jander, S. et al., Interleukin-18 is induced in acute inflammatory demyelinating polymeuropathy, J. Neuroimmunol., vol. 114, pp. 253-258, Mar. 2001. |
Joshi et al., Potent inhibition of human immunodeficiency virus type 1 replection by template analog reverse transcriptase , J. Virol., 76(13), pp. 6545-6557, Jul. 2002. |
Kawahara et al.; SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span.; Cell. ; vol. 136; No. 1; pp. 62-74; Jan. 2009. |
Kalishevskaya et al. “The character of vagotomy-and atropin-induced hypercoagulation,” Sechenov Physiological Journal of the USSR, 65(3): pp. 398-404, Mar. 1979. |
Kalishevskaya et al.; Nervous regulation of the fluid state of the blood; Usp. Fiziol. Nauk;,vol. 13; No. 2; pp. 93-122; Apr.-Jun. 1982. |
Kanai, T. et al., Interleukin-18 and Crohn's disease, Digestion, vol. 63, suppl. 1, pp. 37-42, (year of pub. sufficiently earlier than effective US filing date and any foreign priority date) 2001. |
Katagiri, M., et al., Increased cytokine production by gastric mucosa in patients with helicobacter pylon infection, J. Clin, Gastroenterol., vol. 25, Suppl. 1, pp. S211-S214, 1997. |
Kawashima, et al., Extraneuronal cholinergic system in lymphocytes, Pharmacology & Therapeutics, vol. 86, pp. 29-48, Apr. 2000. |
Kees et al; Via beta-adrenoceptors, stimulation of extrasplenic sympathetic nerve fibers inhibits lipopolysaccharide-induced TNF secretion in perfused rat spleen; J.Neuroimmunol.; 145(1-2); pp. 77-85; Dec. 2003. |
Kensch et al., HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity, J. Biol. Chem., 275(24), pp. 18271-18278, Jun. 16, 2000. |
Khatun, S., et al., “Induction of hypercoagulability condition by chronic localized cold stress in rabbits,” Thromb. and Haemost., 81(3): pp. 449-455, Mar. 1999. |
Kimball, et al., Levamisole causes differential cytokine expression by elicited mouse peritoneal macrophases, Journal of Leukocyte Biology, vo. 52, No. 3, pp. 349-356, Sep. 1992 (abstract only). |
Kimmings, A. N., et al., Systemic inflammatory response in acute cholangitis and after subsequent treatment, Eur. J. Surg., vol. 166, pp. 700-705, Sep. 2000. |
Kirchner et al.; Left vagus nerve stimulation suppresses experimentally induced pain; Neurology; vol. 55; pp. 1167-1171; Oct. 2000. |
Kokkula, R. et al., Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity, Arthritis Rheum., 48(7), pp. 2052-2058, Jul. 2003. |
Koopman et al.; Pilot study of stimulation of the cholinergic anti-inflammatory pathway with an implantable vagus nerve stimulation device in patients with rheumatoid arthritis; Arth. Rheum.; 64(10 suppl.); pp. S195; Oct. 2012. |
Krarup et al; Conduction studies in peripheral cat nerve using implanted electrodes: I. methods and findings in controls; Muscle & Nerve; vol. 11; pp. 922-932; Sep. 1988. |
Kudrjashov, et al. “Reflex nature of the physiological anticoagulating system,” Nature, vol. 196(4855): pp. 647-649; Nov. 17, 1962. |
Kumins, N. H., et al., Partial hepatectomy reduces the endotoxin-induced peak circulating level of tumor necrosis factor in rats, SHOCK, vol. 5, No. 5, pp. 385-388, May 1996. |
Kuznik, “Role of the vascular wall in the process of hemostatis,” Usp Sovrem Biol., vol. 75(1): pp. 61-85, 1973. |
Kuznik, et al., “Blood Coagulation in stimulation of the vagus nerve in cats,” Biull. Eskp. Biol. Med., vol. 78(7): pp. 7-9, 1974. |
Kuznik, et al., “Heart as an efferent regulator of the process of blood coagulation and fibrinolysis,” Kardiologiia, vol. 13(3): pp. 10-17, 1973. |
Kuznik, et al., “Role of the heart and vessels in regulating blood coagulation and fibrinolysis,” Kagdiologiia, vol. 13(4): pp. 145-154, 1973. |
Kuznik, et al., “Secretion of blood coagulation factors into saliva under conditions of hypo-and hypercoagulation,” Voprosy Meditsinskoi Khimii, vol. 19(1): pp. 54-57; 1973. |
Kuznik, et al., “The dynamics of procoagulatible and fibrinolytic activities during electrical stimulation of peripheral nerves,” Sechenov Physiological Journal of the USSR, vol. 65; No. 3: pp. 414-420, Mar. 1979. |
Kuznik, et al., “The role of the vascular wall in the mechanism of control of blood coagulation and fibrinolysis on stimulation of the vagus nerve,” Cor Vasa, vol. 17(2): pp. 151-158, 1975. |
Lang, et al., “Neurogienic control of cerebral blood flow,” Experimental Neurology, 43(1): pp. 143-161, Apr. 1974. |
Lee, H. G., et al., Peritoneal lavage fluids stimulate NIH3T3 fibroblast proliferation and contain increased tumour necrosis factor and IL6 in experimental silica-induced rat peritonitis, Clin. Exp. Immunol., vol. 100, pp. 139-144, Apr. 1995. |
LeNovere, N. et al., Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells, J. Mol. Evol., 40, pp. 155-172, Feb. 1995. |
Leonard, S. et al., Neuronal nicotinic receptors: from structure to function, Nicotine & Tobacco Res. 3:203-223, Aug. 2001. |
Lips et al.; Coexpression and spatial association of nicotinic acetylcholine receptor subunits alpha7 and alpha10 in rat sympathetic neurons; J.Mol.Neurosci.; 30; pp. 15-16; Feb. 2006. |
Lipton, J. M. et al.; Anti-inflammatory actions of the neuroimmunomodulator ?-MSH, Immunol. Today, vol. 18, pp. 140-145, Mar 1997. |
Loeb et al.; Cuff electrodes for chronic stimulation and recording of peripheral nerve activity; Journal of Neuroscience Methods; vol. 64; pp. 95-103; Jan. 1996. |
Madretsma, G. S., et al., Nicotine inhibits the in vitro production of interleukin 2 and tumour necrosis factor-alpha by human monocuclear cells, Immunopharmacology, vol. 35, No. 1, pp. 47-51, Oct. 1996. |
Martindale: The Extra Pharmacopoeia; 28th Ed. London; The Pharmaceutical Press; pp. 446-485; © 1982. |
Martiney et al., Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage-deactivating agent, Journal of Immunology, vol. 160, No. 11, pp. 5588-5595, Jun. 1, 1998. |
McGuinness, P. H., et al., Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particulary interleukin 18) in chronic hepatitis C infection, Gut, vol. 46(2), pp. 260-269, Feb. 2000. |
Miguel-Hidalgo, J.J.; The role of glial cells in drug abuse; Current Drug Abuse Reviews; vol. 2; No. 1; pp. 76-82; Jan. 2009. |
Milligan et al.; Pathological and protective roles of glia in chronic pain; Nat Rev Neurosci.; vol. 10; No. 1; pp. 23-26; Jan. 2009. |
Minnich et al.; Anti-cytokine and anti-inflammatory therapies for the treatment of severe sepsis: progress and pitfalls; Proceedings of the Nutrition Society; vol. 63(3); pp. 437-441; Aug. 2004. |
Mishchenko, et al., “Coagulation of the blood and fibrinolysos in dogs during vagal stimulation,” Sechenov Physiological Journal of the USSR, vol. 61(1): pp. 101-107, 1975. |
Mishchenko, “The role of specific adreno-and choline-receptors of the vascular wall in the regulation of blood coagulation in the stimulation of the vagus nerve,” Biull. Eskp. Biol. Med., vol. 78(8): pp. 19-22, 1974. |
Molina et al., CNI-1493 attenuates hemodynamic and pro-inflammatory responses to LPS, Shock, vol. 10, No. 5, pp. 329-334, Nov. 1998. |
Nadol et al., “Surgery of the Ear and Temporal Bone,” Lippinkott Williams & Wilkins, 2nd Ed., 2005, (Publication date: Sep. 21, 2004), p. 580. |
Nagashima et al., Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life, J. Clin. Invest., 109, pp. 101-110, Jan. 2002. |
Nathan, C. F., Secretory products of macrophages, J. Clin. Invest., vol. 79 (2), pp. 319-326, Feb. 1987. |
Navalkar et al.; Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis; Journal of the American College of Cardiology; vol. 37; No. 2; pp. 440-444; Feb. 2001. |
Navzer et al.; Reversing pathological neural activity using targeted plasticity; Nature; 470(7332); pp. 101-104; Feb. 3, 2011. |
Neuhaus et al.; P300 is enhanced in responders to vagus nerve stimulation for treatment of major depressive disorder; J. Affect. Disord.; 100(1-3); pp. 123-128; Jun. 2007. |
Noguchi et al., Increases in Gastric acidity in response to electroacupuncture stimulation of hindlimb of anesthetized rats, Jpn. J. Physiol., 46(1), pp. 53-58, Feb. 1996. |
Norton, Can ultrasound be used to stimulate nerve tissue, BioMedical Engineering OnLine, 2(1), pp. 6, Mar. 4, 2003. |
Olofsson et al.; Rethinking inflammation: neural circuits in the regulation of immunity; Immunological Reviews; 248(1); pp. 188-204; Jul. 2012. |
Oshinsky et al.; Non-invasive vagus nerve stimulation as treatment for trigeminal allodynia; Pain; 155(5); pp. 1037-1042; May 2014. |
Palmblad et al., Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis: a thereapeutic study unding a macrophage-deactivation compound, American Journal of Pathology, vol. 158, No. 2, pp. 491-500, Feb. 2, 2001. |
Pateyuk, et al.,“Treatment of Botkin's disease with heparin,” Klin. Med., vol. 51(3): pp. 113-117, Mar. 1973. |
Pavlov et al; Controlling inflammation: the cholinergic anti-inflammatory pathway; Biochem. Soc. Trans.; 34(Pt 6); pp. 1037-1040; Dec. 2006. |
Payne, J. B. et al., Nicotine effects on PGE2 and IL-1 beta release by LPS-treated human monocytes, J. Perio. Res., vol. 31, No. 2, pp. 99-104, Feb. 1996. |
Peuker; The nerve supply of the human auricle; Clin. Anat.; 15(1); pp. 35-37; Jan. 2002. |
Prystowsky, J. B. et al., Interleukin-1 mediates guinea pig gallbladder inflammation in vivo, J. Surg. Res., vol. 71, No. 2, pp. 123-126, Aug. 1997. |
Pulkki, K. J., Cytokines and cardiomyocyte death, Ann. Med., vol. 29(4), pp. 339-343, Aug. 1997. |
Pullan, R. D., et al., Transdermal nicotine for active ulceratiive colitis, N. Engl. J. Med., vol. 330, No. 12, pp. 811-815, Mar. 24, 1994. |
Pulvirenti et al; Drug dependence as a disorder of neural plasticity:focus on dopamine and glutamate; Rev Neurosci.; vol. 12; No. 2; pp. 141-158; Apr./Jun. 2001. |
Rahman et al.; Mammalian Sirt 1: Insights on its biological functions; Cell Communications and Signaling; vol. 9; No. 11; pp. 1-8; May 2011. |
Rayner, S. A. et al., Local bioactive tumour necrosis factor (TNF) in corneal allotransplantation, Clin. Exp. Immunol., vol. 122, pp. 109-116, Oct. 2000. |
Reale et al.; Treatment with an acetylcholinesterase inhibitor in alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines; J. Neuroimmunology; 148(1-2); pp. 162-171; Mar. 2004. |
Rinner et al.; Rat lymphocytes produce and secrete acetylcholine in dependence of differentiation and activation; J.Neuroimmunol.; 81(1-2); pp. 31-37; Jan. 1998. |
Robinson et al.; Studies with the Electrocardiograph on the Action of the Vagus Nerve on the Human Heart; J Exp Med; 14(3):217-234; Sep. 1911. |
Romanovsky, A. A., et al.,The vagus nerve in the thermoregulatory response to systemic inflammation, Am. J. Physiol., vol. 273, No. 1 (part 2), pp. R407-R413, Jul. 1, 1997. |
Saghizadeh et al.; The expression of TNF? by human muscle; J. Clin. Invest.; vol. 97; No. 4; pp. 1111-1116; Feb. 15, 1996. |
Saindon et al.; Effect of cervical vagotomy on sympathetic nerve responses to peripheral interleukin-1beta; Auton.Neuroscience Basic and Clinical; 87; pp. 243-248; Mar. 23, 2001. |
Saito, Involvement of muscarinic M1 receptor in the central pathway of the serotonin-induced bezold-jarisch reflex in rats, J. Autonomic Nervous System, vol. 49, pp. 61-68, Sep. 1994. |
Sandborn, W. J., et al., Transdermal nicotine for mildly to moderately active ulcerative colitis, Ann. Intern. Med, vol. 126, No. 5, pp. 364-371, Mar. 1, 1997. |
Sato, E., et al., Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity, Am. J. Physiol., vol. 274, pp. L970-L979, Jun. 1998. |
Sato, K.Z., et al., Diversity of mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear leukosytes and leukemic cell lines, Neuroscience Letters, vol. 266, pp. 17-20, Apr. 30, 1999. |
Scheinman, R. I., et al., Role of transcriptional activation of I?B? in mediation of immunosuppression by glucocorticoids, Science, vol. 270, No. 5234, pp. 283-286, Oct. 13, 1995. |
Schneider et al., High-affinity ssDNA inhibitors of the review transcriptase of type human immunodeficiency virus, Biochemistry, 34(29), pp. 9599-9610, Jul. 1995. |
Shafer, Genotypic testing for human immunodeficiency virus type 1 drug resistance, Clinical Microbiology Reviews, vol. 15, pp. 247-277, Apr. 2002. |
Shapiro et al.; Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery; Thromb Haemost; vol. 80(5); pp. 773-778; Nov. 1998. |
Sher, M. E., et al., The influence of cigarette smoking on cytokine levels in patients with inflammatory bowel disease, Inflamm. Bowel Dis., vol. 5, No. 2, pp. 73-78, May 1999. |
Shi et al.; Effects of efferent vagus nerve excitation on inflammatory response in heart tissue in rats with endotoxemia; vol. 15, No. 1; pp. 26-28; Jan. 2003 (Eng. Abstract). |
Snyder et al., Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors; Nature Medicine, 5(1), pp. 64-70, Jan. 1999. |
Sokratov, et al. “The role of choline and adrenegic structures in regulation of renal excretion of hemocoagulating compounds into the urine,” Sechenov Physiological Journal of the USSR, vol. 63(12): pp. 1728-1732, 1977. |
Stalcup et al., Endothelial cell functions in the hemodynamic responses to stress, Annals of the New York Academy of Sciences, vol. 401, pp. 117-131, Dec. 1982. |
Steinlein, New functions for nicotine acetylcholine receptors?, Behavioural Brain Res., vol. 95(1), pp. 31-35, Sep. 1998. |
Sternberg, E. M., Perspectives series: cytokines and the brain ‘neural-immune interactions in health and disease,’ J. Clin. Invest., vol. 100, No. 22, pp. 2641-2647, Dec. 1997. |
Stevens et al.; The anti-inflammatory effect of some immunosuppressive agents; J. Path.; 97(2); pp. 367-373; Feb. 1969. |
Strojnik et al.; Treatment of drop foot using and implantable peroneal underknee stimulator; Scand. J. Rehab. Med.; vol. 19(1); pp. 37R43; Dec. 1986. |
Sugano et al., Nicotine inhibits the production of inflammatory mediators in U937 cells through modulation of nuclear factor-kappaβ activation, Biochemical and Biophysical Research Communications, vol. 252, No. 1, pp. 25-28, Nov. 9, 1998. |
Suter et al.; Do glial cells control pain?; Neuron Glia Biol.; vol. 3; No. 3; pp. 255-268; Aug. 2007. |
Swick et al.; Locus coeruleus neuronal activity in awake monkeys: relationship to auditory P300-like potentials and spontaneous EEG. Exp. Brain Res.; 101(1); pp. 86-92; Sep. 1994. |
Sykes, et al., An investigation into the effect and mechanisms of action of nicotine in inflammatory bowel disease, Inflamm. Res., vol. 49, pp. 311-319, Jul. 2000. |
Takeuchi et al., A comparision between chinese blended medicine “Shoseiryuto” tranilast and ketotifen on the anit-allergic action in the guinea pigs, Allergy, vol. 34, No. 6, pp. 387-393, Jun. 1985 (eng. abstract). |
Tekdemir et al.; A clinico-anatomic study of the auricular branch of the vagus nerve and arnold's ear-cough reflex; Surg. Radiol. Anat.; 20(4); pp. 253-257; Mar. 1998. |
Toyabe, et al., Identification of nicotinic acetylcholine receptors on lymphocytes in the periphery as well as thymus in mice, Immunology, vol. 92(2), pp. 201-205, Oct. 1997. |
Tracey et al., Mind over immunity, Faseb Journal, vol. 15, No. 9, pp. 1575-1576, Jul. 2001. |
Tracey, K. J. et al., Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia; Nature, 330: pp. 662-664, Dec. 23, 1987. |
Tracey, K. J. et al., Physiology and immunology of the cholinergic antiinflammatory pathway; J Clin Invest.; vol. 117: No. 2; pp. 289-296; Feb. 2007. |
Tracey, K. J.; Reflex control of immunity; Nat Rev Immunol; 9(6); pp. 418-428; Jun. 2009. |
Tracey, K. J. et al., Shock and tissue injury induced by recombinant human cachectin, Science, vol. 234, pp. 470-474, Oct. 24, 1986. |
Tracey, K.J., The inflammatory reflex, Nature, vol. 420, pp. 853-859, Dec. 19-26, 2002. |
Tsutsui, H., et al., Pathophysiolocical roles of interleukin-18 in inflammatory liver diseases; Immunol. Rev., 174:192-209, Apr. 2000. |
Tuerk et al., RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase; Proc. Natl. Acad. Sci. USA, 89, pp. 6988-6992, Aug. 1992. |
Tuerk et al., Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase; Science, 249(4968), pp. 505-510, Aug. 3, 1990. |
Van Dijk, A. P., et al., Transdermal nictotine inhibits interleukin 2 synthesis by mononuclear cells derived from healthy volunteers, Eur. J. Clin. Invest, vol. 28, pp. 664-671, Aug. 1998. |
Van Der Horst et al.; Stressing the role of FoxO proteins in lifespan and disease; Nat Rev Mol Cell Biol.; vol. 8; No. 6; pp. 440-450; Jun. 2007. |
Vanhoutte, et al., Muscarinic and beta-adrenergic prejunctional modulation of adrenergic neurotransmission in the blood vessel wall, Gen Pharmac., vol. 14(1), pp. 35-37, Jan. 1983. |
VanWesterloo, et al., The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis, The Journal of Infectious Diseases, vol. 191, pp. 2138-2148, Jun. 15, 2005. |
Ventureyra, Transcutaneous vagus nerve stimulation for partial onset seizure therapy, Child's Nerv Syst, vol. 16(2), pp. 101-102, Feb. 2000. |
Vijayaraghavan, S.; Glial-neuronal interactions-implications for plasticity anddrug addictionl AAPS J.; vol. 11; No. 1; pp. 123-132; Mar. 2009. |
Villa et al., Protection against lethal polymicrobial sepsis by CNI-1493, an inhibitor of pro-inflammatory cytokine synthesis, Journal of Endotoxin Research, vol. 4, No. 3, pp. 197-204, Jun. 1997. |
Von Känel, et al., Effects of non-specific ?-adrenergic stimulation and blockade on blood coagulation in hypertension, J. Appl. Physiol., vol. 94, pp. 1455-1459, Apr. 2003. |
Von Känel, et al., Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo, Eur. J. Haematol., vol. 65: pp. 357-369, Dec. 2000. |
Walland et al., Compensation of muscarinic brochial effects of talsaclidine by concomitant sympathetic activation in guinea pigs; European Journal of Pharmacology, vol. 303(2-3), pp. 213-219, Jul. 9, 1997. |
Wang et al; Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation; Nature; 421; 384-388; Jan. 23, 2003. |
Wang, H., et al., HMG-1 as a late mediator of endotoxin lethality in mice, Science, vol. 285, pp. 248-251, Jul. 9, 1999. |
Waserman, S. et al., TNF-? dysregulation in asthma: relationship to ongoing corticosteroid therapy, Can. Respir. J., vol. 7, No. 3, pp. 229-237, May-Jun. 2000. |
Watanabe, H. et al., The significance of tumor necrosis factor (TNF) levels for rejection of joint allograft, J. Reconstr. Microsurg., vol. 13, No. 3, pp. 193-197, Apr. 1997. |
Wathey, J.C. et al., Numerical reconstruction of the quantal event at nicotinic synapses; Biophys. J., vol. 27: pp. 145-164, Jul. 1979. |
Watkins, L.R. et al., Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication, Neurosci. Lett., vol. 183(1-2), pp. 27-31, Jan. 1995. |
Watkins, L.R. et al., Implications of immune-to-brain communication for sickness and pain, Proc. Natl. Acad. Sci. U.S.A., vol. 96(14), pp. 7710-7713, Jul. 6, 1999. |
Webster's Dictionary, definition of “intrathecal”, online version accessed Apr. 21, 2009. |
Weiner, et al., “Inflammation and therapeutic vaccination in CNS diseases,” Nature., vol. 420(6917): pp. 879-884, Dec. 19-26, 2002. |
Westerheide et al.; Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1.; Science; Vo. 323; No. 5717; pp. 1063-1066; Feb. 2009. |
Whaley, K. et al., C2 synthesis by human monocytes is modulated by a nicotinic cholinergic receptor, Nature, vol. 293, pp. 580-582, Oct. 15, 1981. |
Woiciechowsky, C. et al., Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury, Nature Med., vol. 4, No. 7, pp. 808-813, Jul. 1998. |
Yeh, S.S. et al., Geriatric cachexia: the role of cytokines, Am. J. Clin. Nutr., vol. 70(2), pp. 183-197, Aug. 1999. |
Yu et al.; Low-level transcutaneous electrical stimulation of the auricular branch of the vagus nerve: a non-invasive approach to treat the initial phase of atrial fibrillation; Heart Rhythm; 10(3); pp. 428-435; Mar. 2013. |
Zamotrinsky et al.; Vagal neurostimulation in patients with coronary artery disease; Auton. Neurosci.; 88(1-2); pp. 109-116; Apr. 2001. |
Zhang et al., Tumor necrosis factor, The Cytokine Handbook, 3rd ed., Ed. Thompson, Academic Press, pp. 517-548, Jul. 1, 1998. |
Zhang et al.; Roles of SIRT1 in the acute and restorative phases following induction of inflammation.; J Biol Chem.; vol. 285; No. 53; pp. 41391-41401; Dec. 2010. |
Zhang et al.; Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model; Circulation Heart Fail.; 2; pp. 692-699; Nov. 2009. |
Zhao et al.; Transcutaneous auricular vagus stimulation protects endotoxemic rat from lipopolysaccharide-induced inflammation; Evid. Based Complement Alternat. Med.; vol. 2012; Article ID 627023; 10 pages; Dec. 29, 2012. |
Levine et al.; U.S. Appl. No. 15/398,615 entitled “Devices and methods for modulation of bone erosion,” filed Jan. 4, 2017. |
Faltys et al.; U.S. Appl. No. 15/406,619 entitled “Systems and methods for establishing a nerve block,” filed Jan. 13, 2017. |
Levine et al.; U.S. Appl. No. 15/411,933 entitled “Control of vagal stimulation,” filed Jan. 20, 2017. |
Zitnik et al.; U.S. Appl. No. 15/411,936 entitled “Implantable microstimulators and inductive charging systems,” filed Jan. 20, 2017. |
Tracey et al., U.S. Appl. No. 16/231,581 entitled “Inhibition of inflammatory cytokine production by cholinergic agnostics and vagus nerve stimulation,” filed Dec. 23, 2018. |
Levine et al.; U.S. Appl. No. 15/853,350 entitled “Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation,” filed Dec. 22, 2017. |
Manta et al.; Optimization of vagus nerve stimulation parameters using the firing activity of serotonin neurons in the rat dorsal raphe; European Neuropsychopharmacology; vol. 19; pp. 250-255; Jan. 2009 (doi: 10.1016/j.euroneuro.2008.12.001). |
Pongratz et al.; The sympathetic nervous response in inflammation; Arthritis Research and Therapy; 16(504); 12 pages; retrieved from the internet (http://arthritis-research.com/content/16/6/504) ; Jan. 2014. |
Faltys et al.; U.S. Appl. No. 16/005,191 entitled “Neural stimulation devices and systems for treatment of chronic inflammation,” filed Jun. 11, 2018. |
Zitnik et al.; U.S. Appl. No. 16/356,906 entitled “Batteryless Implantable Microstimulators,” filed Mar. 18, 2019. |
Number | Date | Country | |
---|---|---|---|
20170209705 A1 | Jul 2017 | US |
Number | Date | Country | |
---|---|---|---|
62286951 | Jan 2016 | US | |
62340937 | May 2016 | US | |
62286955 | Jan 2016 | US |